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 CHAPTER I 
INTRODUCTION 
 
1.1 Background 
In plant, nitrogen is a critical limiting element for plant growth and production 
thus it is applied as N­fertilizer to increase yield of important crops. However, the 
excess uses of nitrogen fertilizer have various adverse effects on soil, such as depletes 
water holding capacity, soil fertility and disparity in soil nutrients and water pollution.  
Therefore, a number of microorganisms (bacteria, fungi and algae) are considered as 
beneficial for agriculture and used as bio­fertilizers (Pedraza 2008). Rhizobium is one 
of biofertilizers that can nodulate specific leguminous plants and able to fix nitrogen 
from the atmosphere into the plants themselves. This process is called "Biological 
Nitrogen Fixation" (BNF). Nowadays, the BNF approach becomes a very attractive 
and promising alternative to expensive nitrogen chemical fertilizers. However, the 
number of rhizobia in the soil are low or containing higher number of ineffective 
strain. In order to take advantage of this association of bacteria and leguminous 
plants, it is often necessary to provide suitable legume inoculants to assure effective 
nodulation of leguminous crops. The application of these bacteria to seed or soil is 
called "inoculum" (Burton 1984). 
The key success of having high quality legume inoculant is an effective 
quality control system. The rhizobial strain must be identified and the number of cell 
should be higher than the standard with no contamination (Olsen et al. 1996). 
Therefore, several methods are needed to validate the identity and quantity of specific 
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rhizobia in the inoculant. Nowadays, there are many methods for detection and 
monitoring of rhizobia in quality control procedures, such as microbiological 
techniques, immunological techniques and molecular techniques (Olsen et al. 1996). 
The immunological techniques used widely in quality control procedures to obtain 
information about rhizobial cultures and products.  However, polyclonal antibody is 
very often to have cross­reactivity with other rhizobial strains within the same 
species.  This cross­reactivity may also extend to other rhizobial biovars or species 
and sometimes even to members of other bacterial genera (Olsen et al. 1996).  These 
cross­reactions are the main problem of using polyclonal antibody to detect and 
monitor specific rhizobium.  The hybridoma technology which enabled a deﬁned 
speciﬁcity of monoclonal antibodies (mAbs) has been introduced to produce mAbs in 
consistent quality and in large quantities in the laboratory (Kohler et al. 1975). Since 
then, mAbs have been favored as they can be produced in unlimited quantities to 
practically bind to any antigen and are more easily standardized. However, mAbs face 
diﬃculties in production. The monoclonal antibody producing technology is 
laborious, time consuming, and costly (Ahmad et al. 2012), thus it is difficult to be 
produced and applied in agriculture. 
Comparing to all antibody ­ based methods, phage display technology offers 
an attractive way of producing antibodies against diverse antigens. The phage display 
technique allowed isolation of antibodies directly from diverse repertoires of antibody 
genes. These antibody genes are expressed on the surface of filamentous 
bacteriophage as fusion proteins (Smith 1985, McCafferty et al. 1990, Smith et al. 
1997). Recently, the technology has been improved through recombinant DNA 
technology and antibody engineering whereby antibody genes can now be cloned and 
expressed successfully as a fragment in many expression systems such as, bacteria 
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(Skerra et al. 1988), mammalian cell and yeast (Ho et al. 2006), plant (Galeffi et al. 
2006), and also insect cells (Choo et al. 2002). One advantage of this new technology 
is that they could retain the intact antigen binding site (paratope) while reducing the 
size of the antibody molecule. In addition, the combination of small antibody 
molecule together with the efficient microbial production systems can finally lead to 
the production of a homogenous protein in sufficient amounts for diagnostic and 
therapeutic purposes as well as in structural studies (Ahmad et al. 2012). 
Bradyrhizobium sp. DOA9, a non­photosynthetic bradyrhizobial strain was 
isolated from Aeschynomene americana L. in Thailand. Previous study based on 
phenotypic characteristics and sequence analysis of 16sRNA and 3 housekeeping 
genes (dnaK, recA, glnB) confirming that this strain is closely related to B. 
yuanmingense. This strain has board host range and be able to nodulate several 
legumes and colonize rice plant (Noisangiam et al. 2012). Thus, this strain has great 
potential in inoculant production for bio­fertilizers. 
Thus, it is interesting to develop antibody specific to Bradyrhizobium sp. 
DOA9 by using engineering antibody through phage display technique to reduce the 
problem of cross­reaction occurring from polyclonal antibody or difficulty in 
monoclonal antibody production. 
 
1.2 Research objectives 
To construct a recombinant single­chain variable fragment antibody (scFv) 
against nitrogen fixing bacteria Bradyrhizobium sp. DOA9 for agricultural 
application. 
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Specific objectives for this thesis are: 
1. To construct a phage displayed single chain fragment variable (scFv) 
antibodies from rabbit immunized with nitrogen fixing bacteria Bradyrhizobium sp. 
DOA9. 
2. To affinity select phage displayed scFv antibodies which are specific to 
Bradyrhizobium sp. DOA9 by bio­panning from naïve human antibody and 
immunized rabbit antibody constructed from step 1. 
3. To verify the selected single chain fragment variable (scFv) for the 
detection of Bradyrhizobium sp. DOA9 in different agricultural processes. 
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CHAPTER II 
LITERATURE REVIEWS 
 
2.1 Biological Nitrogen Fixation (BNF) 
In nature, some prokaryotes can convert atmospheric nitrogen into a form that 
plants can use. They utilize the nitrogenase enzyme to catalyze the conversion of 
atmospheric nitrogen (N2) to ammonia (NH3). This process is called biological 
nitrogen fixation (BNF). They consist of aquatic organisms, such as cyanobacteria, 
free­living soil bacteria, such as Azotobacter, bacteria that form associative 
relationships with plants, such as Azospirillum, and most importantly, bacteria 
Rhizobia, such as Rhizobium and Bradyrhizobium that form symbioses with legumes 
and other plants (Sessitscha et al. 2002). 
The enzyme nitrogenase catalyzes the breaking of hydrogen bond and the 
addition of three hydrogen atoms to each nitrogen atom. Microorganisms that fix 
nitrogen require 16 moles of adenosine triphosphate (ATP) to reduce each mole of 
nitrogen. They obtain this energy by oxidizing organic molecules. Non­photosynthetic 
free­living microorganisms must obtain these molecules from other organisms, while 
photosynthetic microorganisms, such as cyanobacteria, use sugars produced by 
photosynthesis. The symbiotic nitrogen­fixing microorganisms obtain these 
compounds from their host plants (Bhattacharjee et al. 2008). 
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 2.1.1 Rhizobia 
Rhizobia are the general name given to a diverse group of soil bacteria 
which are able to symbiosis with leguminous plants. They are gram­negative 
chemoheterotrophic organotroph bacilli that live freely in the soil. Rhizobia could 
form the specialized organs, called nodules, on roots or stems of leguminous hosts. 
The nodule inside bacteria could convert atmospheric nitrogen into ammonia, 
providing the nitrogen requirements of both rhizobia and their host plants. In feedback 
way, the plant feeds sugars, proteins, and oxygen for the bacteria (Sessitscha et al. 
2002). 
In the past, rhizobia were divided into two groups depending on growth 
rate: Rhizobium and Bradyrhizobium. The firstly genus, Rhizobium is the fast­growing 
acid producers that develop pronounced turbidity in liquid media within 2­3 days and 
have a mean doubling time of 2­4 h. The cells are motile by two to six peritrichous 
flagella. They can grow on a wide range of carbohydrates, but usually grow best on 
glucose, mannitol, or sucrose. This group is generally effective on temperate legumes. 
The second genus, Bradyrhizobium, is emerged as the genus of the slow­growing and 
alkaline­producing rhizobial strains. They are the slow­growing, alkali­producing 
rhizobia, collectively known as bradyrhizobia. They require 3­5 days to produce 
moderate turbidity in liquid media and have a mean doubling time of 6­8 h. Most 
strains in this group grow best with pentoses as their carbon source. The cells are 
motile by a single polar or subpolar flagellum. A large genera of tropical legume 
species are nodulated by bradyrhizobia (Somasegaran et al. 1994). 
The classification and taxonomy of rhizobia is becoming increasingly 
complex and is revised periodically because of new findings that propose new genera 
and new species. DNA homology values, guanine­cytosine (GC) content, sequence 
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homologies of multiple loci (such as small subunit ribosomal RNA gene (16S rDNA), 
house­keeping genes and symbiotic genes), locations of symbiotic genes and 
phenotypic characteristics provide more and deeper information for the classification 
of rhizobia (Pongsilp 2012). 
To date, rhizobia have been classified into six genera, including 
Azorhizobium, Bradyrhizobium, Mesorhizobium, Allorhizobium, Sinorhizobium, and 
Rhizobium (Martinez­Romero et al. 2000, Teamroong et al. 2006, Pongsilp 2012). 
The current genera of Rhizobiaceae are summarized in Table 2.1 
 
 2.1.2 Rhizobial antigens 
 Antigens of rhizobia can be categorized into somatic, flagella, and 
capsular, depending on their derivation. Somatic antigens are closely related to the 
rhizobial cell wall and are usually designated by the letter O. Some somatic antigens 
may be tightly bound to the cell wall, in which case they are not removed by washing 
of the cells. Therefore, these antigens are only detected when whole cells of rhizobia 
react with the antibody, as in agglutination or immunofluorescence. The somatic 
antigens that are soluble and easily removed by washing are detected by precipitation 
in gel. Somatic antigens are also heat stable. They are the most specific of the three 
groups of antigens. 
 The precipitating "internal antigens" are more widely shared and 
taxonomically significant. These are released from cells having fragile or broken 
walls. Because internal antigens are widely cross­reactive within and between species, 
they require recognition and interpretation in gel immune­diffusion. 
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Table 2.1 Current taxonomy of rhizobia (Martinez­Romero et al. 2000). 
 
Genus 
 
Species 
 
Host 
 
Allorhizobium 
 
A. undicola 
 
Nepunia natans 
Azorhizobium A. caulinodans Sesbania rostrata 
Bradyrhizobium B. elkanii 
B. japonicum 
B. liaoningense 
Glycine max 
G. max 
G. max 
Mesorhizobium M. amorphae 
M. cicero 
M. huakuii 
M. loti 
M. mediterraneum 
M. plurifarium 
M. tianshanse 
Amorpha fructicosa 
Cicer arietinum 
Astragalus 
Lotus japonicas 
C. arietinum 
Acacia, Leucaena 
Glycyrrhiza, Sophora, Glycine and 
others 
Rhizobium R. etli 
R. galegae 
R. gallicum 
R. giardinii 
R. hainanense 
 
R. huantlense 
R. leguminosarum 
R. mongolense 
R. tropici 
Phaseolus vulgaris, Mimosa affinis 
Galega 
P. vulgaris 
P. vulgaris 
Stylosanthes, Centrocema, 
Desmodium, 
Tephrosia 
S. herbacea 
Vicia, Trifolium 
Medicago ruthenica, P. vulgaris 
P. vulgaris, Leucaena 
Sinorhizobium S. arboris 
S. fredii 
S. kostiense 
S. medicae 
S. meliloti 
S. saheli 
S. terangae 
S. xinjiangense 
A. senegal, Prosopis chilensi 
G. max 
A. senegal, P. chilensis 
Medicago spp. 
M. sativa 
Sesbania 
Sesbania, Acacia 
G. max 
 
 The flagella of the rhizobia are also antigenic and appropriately called 
flagella or H antigens. They are heat labile and are commonly detected by 
agglutination or immunofluorescence test. The extracellular antigens are surface 
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antigens and are found outside the cell itself. They are usually designated by the letter 
K. 
 
2.2 The methods to detect and monitoring of Rhizobia 
Rhizobia that have dramatic differences in such important traits as host 
specificity, invasiveness, and effectiveness are indistinguishable from each other 
under the microscope. However, the detection and monitoring of rhizobial strain after 
introducing to the field are difficult (Somasegaran and Hoben 1994). 
 
 2.2.1 The microbiological techniques 
 Many morphological characteristics and biochemical and metabolic tests 
are frequently used to differentiate among rhizobial species. These tests include 
vitamin requirements, salt, acid and alkali tolerance, carbohydrate utilization, and 
resistance to antibiotics. Numerical analysis employs a large range of biochemical and 
metabolic tests to differentiate among rhizobial species. The results obtained from 
numerical analysis support the proposal of several novel species of rhizobia. 
Rhizobial species vary in their enzymatic production and several enzymes are found 
to be necessary for the symbiotic effectiveness. Carbohydrate utilization properties 
are of taxonomic significance (Somasegaran and Hoben 1994). 
 The possibility of resistance to low levels of antibiotics also can be used 
for rhizobial strain characterization and identification. When high­density inoculant of 
a rhizobial strain is inoculated into media containing an antibiotic, a few cells may 
exhibit resistance as a result of spontaneous genetic changes or mutations. The 
resistance of a rhizobial strain to a particular antibiotic is a useful marker. If the 
mutant strain is used to inoculate a legume, then nodules occupied by that strain may 
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be identified by plating nodule isolates on media containing the respective antibiotic. 
The mutant rhizobial strain will grow on the antibiotic media and other bacteria will 
be suppressed. Streptomycin resistance is frequently used as a marker for rhizobia. 
Mutants resistant to this aminoglycoside are stable, have a low incidence of cross­
resistance, and infrequently lose their symbiotic capacity. Besides streptomycin, 
spectinomycin and rifampicin have also been used (Olsen et al. 1996). 
 
 2.2.2 The immunological techniques 
 When bacteria (including rhizobia) are injected into a mammal, the animal 
produces antibodies which will bind antigens on the surface of the bacteria. As a 
result of antigen injections, complex immunological reactions result in the animal 
producing special proteins called globular antibodies (immunoglobulins). The study 
of the reactions of the immune serum with the antigens outside the animal is known as 
serology. If the surface antigens on the rhizobia are relatively unique and unshared by 
other microorganisms the binding of the antibodies can be used to both detect and 
identify the target rhizobia. Antigen­antibody reactions are highly specific. The 
antibody reacts only with the antigen that elicited its formation. A variety of method 
based on antibody­antigen reactions and which are useful in the detection of rhizobial 
broth or inoculants have been developed. In rhizobial, both cultured cells and nodule 
antigens (bacteroids) are used for strain identification (Olsen et al. 1983, Somasegaran 
and Hoben 1994, Olsen et al. 1996). 
 Nowadays, several methods have been applied to study the phenotypic 
diversity of rhizobia, particularly numerical analysis, enzyme pattern and serological 
study. Serological techniques are the most specific methods for identifying rhizobia 
based on natural marker characteristics. Phenotypic characterization by serotyping has 
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been used widely to study rhizobial populations in different geographical origins. 
Rhizobia in different serogroups have been found predominant among field 
populations (Pongsilp 2012). 
 
 2.2.2.1 Agglutination 
 The process in which the antigens are linked together by their 
corresponding antibodies is called agglutination. The linked antigens may be 
microscopically or macroscopically visible as clumps, agglutinates or aggregates. The 
agglutination reaction depends on a firm structural relationship between an exposed 
bacterial antigen and the antibody. If the antibodies do not bind to the cells, no 
agglutination occurs. Agglutination is commonly used as a method of identifying 
specific bacterial antigens, and in turn, the identity of such bacteria. The agglutination 
test was one of the first methods to be applied to serological investigations of 
rhizobial bacteria. It is among the simplest of serological techniques to use and it has 
been widely applied in many taxonomic and ecologic investigations (Somasegaran 
and Hoben 1994). 
 Advantages: the agglutination reaction is the simplest of all 
immunological procedures and involves only primary antisera.  No secondary 
antibodies or signal producing labels are needed.  The technique is fast and does not 
require specialized equipment and skill. 
 Limitations: The cross­reactivity between rhizobia is common with 
non­adsorbed primary antisera.  The agglutination test is not as sensitive as other 
immunological tests and does not demonstrate cell viability (Olsen et al. 1996). 
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 2.2.2.2 Precipitation 
 In recent years, the precipitation tests of somatic antigens have 
been used widely for rhizobia. The precipitation reaction occurs when certain soluble 
antigens are brought into contact with the corresponding antibody. Precipitation 
differs from agglutination in that the precipitating antigens are not whole bacterial 
cells (cellular), but are proteins or polysaccharide molecules in solution (Somasegaran 
and Hoben 1994). 
 
 2.2.2.3 Immunodiffusion 
 The somatic antigens of many rhizobium strains diffuse slowly in 
the agar gels; they yield either no precipitin bands or only weak bands close to the 
antigen well since the location of bands is dependent upon the relative concentrations 
of diffusable antigens and antibodies (Somasegaran and Hoben 1994). 
 
 2.2.2.4 Immunofluorescence (IF) 
 One of the most sensitive of the serological methods available to 
study rhizobia is the fluorescent antibody (FA) technique.  It allows for the 
visualization and investigation of the antigens of individual cells with the fluorescent 
microscope and requires only small quantities of both antigen and antibody. In 
contrast both agglutination and immunodiffusion require large amount of antigen and 
antisera to give a visible reaction. 
 Certain chemical dyes such as fluorescein isothiocyanate (FITC) 
and lissamine rhodamine have the property of fluorescing when excited by near UV 
light. Rhizobial antibodies developed in rabbits can be conjugated to these fluorescing 
chemical dyes or fluorochromes. In work with rhizobia, the chemical dye commonly 
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used for labeling the specific antibody is FITC, which has an apple­green 
fluorescence upon irradiation with blue light. 
 There are two types of fluorescent antibody techniques, namely the 
direct and indirect immunofluorescence. In the direct method, the specific antiserum 
is conjugated and is used as a stain in the procedure. This is different from the indirect 
method, where the unconjugated (unlabeled) specific or primary antibody is first 
reacted with the antigen smear, and after sufficient time is allowed for antigen­
antibody reaction, the smear is then washed free of excess antiserum. This step is 
followed by staining with the FITC­labeled secondary antibody. 
 In serological work with rhizobia, the specific or primary antibody 
against the rhizobial strain is most often developed in rabbits. The secondary antibody 
is developed by immunization of goats or sheep with purified rabbit immunoglobulins 
from a previously unimmunized rabbit. Thus, the rabbit immunoglobulin serves as an 
antigen for immunization of the goat or sheep. Therefore, the antibody produced in 
the goat or sheep will not only react with the rabbit antiserum, but will also react with 
rhizobial antigen with specific unlabeled rabbit antibody attached when the indirect 
procedure is employed. Though the results are the same, the indirect method is 
considered more sensitive. The indirect method requires the labeling of only the 
immune serum from the goat or sheep, and involves two reaction steps; the indirect 
method is also known to give more nonspecific staining reactions. In the direct 
method, each rabbit antiserum developed against each rhizobial strain must be 
conjugated (Somasegaran and Hoben 1994, Olsen et al. 1996). 
 Fluorescent antibody (FA) has been applied widely in working 
with rhizobia, such as, used to identify strains of rhizobia, to identify the nodule­
bacteria, to detect doubly infected nodules, to study rhizobium in soil, to study 
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population dynamics of R. japonicum in the rhizosphere, and to make quantitative 
studies of rhizobium in soil. The FA test is rapid and simple but requires fluorescent 
microscopy equipment and special skill (Somasegaran and Hoben 1994). 
 
 2.2.2.5 Enzyme-Linked Immunosorbent Assay (ELISA) 
 Enzyme­linked immunosorbent assay (ELISA) is one of the several 
enzyme immunoassays used in detecting antigens and antibodies. Basically, in an 
enzyme immunoassay, either the antibody or antigen is tagged with an enzyme (e.g., 
alkaline phosphatase). After completing the assay, the presence or absence of the 
enzyme­labeled component is detected by the addition of an appropriate substrate 
(e.g., paranitrophenylphosphate) resulting in a colored product. 
 In direct ELISA, the specific antibody (Abl) developed for a 
particular strain of rhizobia is immobilized in the wells of the plate. Excess unreacted 
Abl is washed off. The rhizobial antigen is then added to the Ab1­coated wells. After 
an incubation period, excess unreacted antigen is removed by washing. This is 
followed by the addition of an enzyme­Abl conjugate, which binds to its specific 
antigen. Excess enzyme Abl is washed off. The substrate is then added and the 
reaction is stopped following incubation; the colored product is measured 
colorimetrically by ELISA reader machine. 
 In indirect ELISA, which is more popular with rhizobial workers, 
the antigen is immobilized first in the wells. This is followed by the addition of Abl, 
incubation, and washing. The next reactant added is enzyme­Ab2 conjugate. Ab2 is 
usually sheep or goat antibody against Ab1. The enzyme­Ab2 conjugate specifically 
binds to Ab1. After addition of the substrate, the reaction is completed as with direct 
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ELISA. In both ELISA approaches, a 96­well plastic microtiter plate (solid support) is 
used to immobilize the antigen or antibody. 
 The advantages of ELISA are requirement very small amounts of 
antiserum and no microscopic equipment is necessary. But, ELISA requires a purified 
antigen preparation, either from culture or from a root­nodule (Somasegaran and 
Hoben 1994, Olsen et al. 1996). 
 
 2.2.2.6 Membrane immunoblot 
 The membrane immunoblot procedure is another enzyme 
immunoassay that has been developed to detect antigen or antibodies (proteins) 
immobilized (bound) onto a membrane support. This technique has been applied in 
inoculant quality control and ecological studies of rhizobia. The rhizobial cells 
(antigens) are blotted or applied onto membranes made of nitrocellulose or nylon. 
After incubating, the membrane­bound antigens with the homologous antibody (Abl) 
solution, and washing to remove excess unbound Abl, the membrane is immersed in a 
solution containing enzyme Ab2. As with ELISA, Ab2 is usually sheep or goat 
antibody against Ab1. Ab2 has been conjugated with alkaline phosphatase enzyme 
and binds specifically to Ab1. The assay is completed by the addition of substrate 
reagents. These reagents are a mixture of 5­bromo­4­chloro­3­ indolyl­phosphate 
(BClP) and Nitro Blue Tetrazolium (NBT). 
 This technique is not complex and requires no specialized 
equipment.  However, like all immunological techniques for identifying rhizobia, the 
results of the spot blot test are only as good as the specificity of the anti­rhizobial 
antisera used.  Also, the test does not demonstrate cell viability (Somasegaran and 
Hoben 1994, Olsen et al. 1996). 
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 2.2.3 The DNA-based techniques 
 Nowadays, the DNA­based techniques have been widely used for 
evaluating the genetic diversity of microorganisms. For rhizobial, the several 
techniques have been employed to examine genotypic diversity of rhizobial 
populations and to discriminate among rhizobial strains. These techniques include 
random amplified polymorphic DNA (RAPD), two­primers RAPD (TP­RAPD), 
repetitive sequence based PCR (rep­PCR) and amplified fragment length 
polymorphism (AFLP). The 3 main techniques of rep­PCR are enterobacterial 
repetitive intergenic consensus (ERIC)­PCR, repetitive extragenic palindromic (REP)­
PCR and BOX­PCR. While RAPD uses a single primer to amplify the segments of 
DNA randomly throughout the genome, rep­PCR uses pairs of primers (for ERIC­and 
REP­PCR) or a single primer (for BOX­PCR) to amplify the intervals between 
conserved repeated sequences present in genome. In AFLP, total genomic DNA is 
digested and then ligated to oligonucleotide adapters. A pair of specific primer is used 
to amplify the product from restriction. RAPD, rep­PCR and AFLP are suitable for 
distinguishing strains at species or below levels but they are less valuable for 
taxonomic purpose. TP­RAPD has been developed for taxonomic purpose as the 
patterns of strains in the same species have been found to be identical. The TP­RAPD 
patterns supported the proposal of novel species of rhizobia (Pongsilp 2012). 
 Polymerase chain reaction­restriction fragment length polymorphism 
(PCR­RFLP) is used in determining the genetic relationships based upon PCR and 
restriction analysis. Specific genes, such as small subunit ribosomal RNA gene (16S 
rDNA), large subunit ribosomal RNA gene (23S rDNA), 16S­23S rRNA intergenic 
spacer (IGS) and symbiotic genes have been used in PCR­RFLP. The PCR­RFLP 
profile is used to estimate the genetic diversity of microorganisms. The PCR­RFLP 
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method has been used successfully in the differentiation of rhizobial species (Pongsilp 
2012). 
 Restriction fragment length polymorphism (RFLP) also has been used to 
examine the genotypic diversity of bacteria. The technique is based on restriction 
analysis and hybridization, resulting in the fingerprint patterns. For rhizobia, 
symbiotic genes have been frequently used as probes for hybridization. Based on the 
same approach, the insertion sequences (ISs) can be used as probes, resulting in the 
patterns termed as “IS fingerprints”. The use of ISs as probes for hybridization can 
provide high­resolution fingerprints of rhizobial strains. The ISs have been found to 
be abundant in rhizobia. The distribution of ISs varies widely in both IS type and copy 
number. Several ISs are specific to rhizobial species (Pongsilp 2012). 
 The identification of bacteria based on phenotypic characteristics is 
generally not accurate because several species are very difficult to be distinguished 
phenotypically. F rhizobia, the current classification is mainly based on DNA 
sequences [especially a DNA sequence encoding small subunit ribosomal RNA (16S 
rDNA)], DNA homologies, phylogenetic relationships and the locations of symbiotic 
genes. The 16S rDNA is very useful for estimating the evolutionary relationships and 
identifying bacteria. For bacterial identification, 16S rDNA sequencing is particularly 
important in the case of bacteria with unusual phenotypic profiles, rare bacteria, slow­
growing bacteria, uncultivable bacteria and culture­negative infections. The most 
dramatic progress in microbial phylogeny and taxonomy is based on sequence 
analysis of 16S rDNA. These sequences mainly support the proposal of novel genera 
and species of rhizobia. In some cases, several genera are identical in 16S rDNA 
sequence analysis. The other regions, such as large subunit ribosomal RNA gene (23S 
rDNA) as well as intergenic spacer between 16S and 23S rRNA sequences (16S­23S 
18 
 
IGS), are suitable alternatives for classification and identification purposes. 
Multilocus sequence analysis (MLSA), which employs a set of nucleotide sequences 
including 16S rDNA, house­keeping genes and symbiotic genes, has the greater 
potential for rhizobial classification. Currently, sequence analysis is the most 
promising and useful method for identification of rhizobial genera (Pongsilp 2012). 
 
2.3 Phage display technology as possible tool to detect and monitor 
rhizobia 
 2.3.1 Recombinant antibody 
 An antibody (Ab), also known as an immunoglobulin (Ig), is a large Y­
shape protein produced by plasma cells that is used by the immune system to identify 
and neutralize foreign objects such as bacteria and viruses. The antibody recognizes a 
unique part of the foreign target, called an antigen. Each tip of the "Y" of an antibody 
contains a paratope (a structure analogous to a lock) that is specific for one particular 
epitope (similarly analogous to a key) on an antigen, allowing these two structures to 
bind together with precision. Using this binding mechanism, an antibody can tag a 
microbe or an infected cell for attack by other parts of the immune system, or can 
neutralize its target directly (for example, by blocking a part of a microbe that is 
essential for its invasion and survival). The production of antibodies is the main 
function of the animal immune system. 
 Immunoglobulin G (IgG) is an antibody isotype. It is a protein complex 
composed of four peptide chains­two identical heavy chains and two identical light 
chains arranged in a Y­shape typical of antibody monomers. Each IgG has two 
antigen binding sites. Immunoglobulin G (IgG) is a heterotetrameric molecule 
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consisting of two heavy and two light chains, respectively, which are connected via 
disulfide bonds. Heavy and light chains (HC and LC) also contain intramolecular 
disulfide bonds for stabilization (Edelman 1973). IgG is the most abundant antibody 
isotype found in the circulation, approximately 75% of serum immunoglobulins in 
humans. 
 These structural properties require a sophisticated folding apparatus as 
well as an oxidizing environment for the generation of disulfide bonds. Consequently, 
many traditionally expression hosts do not provide these mechanisms for efficient 
production of IgGs. Therefore, smaller antibody fragments have been developed 
which combine easier production with full antigen binding capacity of an IgG 
(Frenzel et al. 2013). 
 Recently, the technology has been improved by recombinant DNA 
technology and antibody engineering whereby antibody genes can now be cloned and 
expressed successfully as a fragment in bacteria (Skerra and Plückthun 1988), on 
mammalian cell and yeast (Ho et al. 2006), plant (Galeffi et al. 2006) and also insect 
cells (Choo et al. 2002). One advantage of this new technology is that they could 
retain the intact antigen binding site (paratope) while reducing the size of the antibody 
molecule. In comparison to the parental antibody, these minimized antibodies have 
several advantages in clinical practices including better tumor penetration, more rapid 
blood clearance, and lower memory times in non­target tissue. It also could lead to the 
expression of the functional antibody and their fusion in bacteria and also allow their 
display on a filamentous phage. In addition, the combination of small antibody 
molecule together with the efficient microbial production systems can finally lead to 
the production of a homogenous protein in sufficient amounts for diagnostic and 
therapeutic purposes as well as in structural studies (Ahmad et al. 2012). 
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Figure 2.1 Recombinant antibody formats for different applications compared to 
IgG. Red and dark red: variable regions; blue: constant regions; green: 
artificial peptide linkers; yellow: dHLX represents amphiphatic helices 
used for dimerization of scFv fragments (Frenzel et al. 2013). 
 
 The recombinant antibody libraries have some type of libraries, naive 
antibody libraries, immune antibody libraries, synthetic antibody libraries, semi­
synthetic antibody libraries. 
 
 2.3.1.1 Naive antibody libraries 
 Non­immune (or naïve) libraries are derived from natural, 
unimmunized, rearranged V­genes of animal or human. (Pansri et al. 2009). Key 
advantages of single­pot repertoires include: (i) isolation of human antibodies to self, 
non­immunogenic or toxic antigens; (ii) a single library can be used for all antigens; 
(iii) short time needed for antibody generation (2­4 rounds of selection in two weeks); 
and (iv) direct isolation of high affinity antibodies when very large repertoires are 
used. Disadvantages of naïve libraries are: (i) low affinity of antibodies isolated from 
small sized libraries; (ii) the time needed to construct large libraries, and (iii) content 
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and quality of the library are influenced by the unequal expression of the V­genes 
repertoire, unknown history of the B­cell donor, and potential limited diversity of the 
IgM repertoire (Azzazy et al. 2002). 
 
 2.3.1.2 Immune antibody libraries 
 In this library, V­genes are derived from the IgG mRNA of B­cells 
from an immunized animal. Immune libraries are advantageous in that antigen­
specific and affinity­matured clones are enriched (Weisser et al. 2009). However, 
disadvantages of immune libraries include: (i) long time required for animal 
immunization, (ii) lack of immune response to self or toxic antigens, (iii) the 
unpredictability of the immune response to the antigen of interest, (iv) a new antibody 
library must be constructed for each antigen (this increases the total time of the 
procedure by 1­3 months), and (v) restrictions in generating human antibodies 
(Azzazy and Highsmith 2002). 
 
 2.3.1.3 Synthetic antibody libraries 
 Synthetic repertoires are libraries in which the antibodies are built 
artificially by in vitro assembly of V, D and J gene segments. Artificial V­genes 
assembly can include introducing a predetermined level of randomization of CDR 
regions into germline V­gene segments (Azzazy and Highsmith 2002, Zhou et al. 
2011). 
 
 2.3.1.4 Semi-synthetic antibody libraries 
 Semi­synthetic libraries combine elements of natural and synthetic 
diversity and often are engineered to increase natural diversity while maintaining a 
certain level of synthetically introduced functional diversity (Zhou et al. 2011). 
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 2.3.2 Single chain fragment variable (scFv) 
 The variable fragment is the smallest unit of immunoglobulin molecule 
with function in antigen­binding activities. An antibody in scFv format consists of 
variable regions of heavy (VH) and light (VL) chains, which are joined together by a 
flexible peptide linker that can be easily expressed in functional form in E. coli, 
allowing protein engineering to improve the properties of scFv such as increase of 
affinity and alteration of specificity (Griffiths et al. 1998). 
 The length of the flexible DNA linker used to link both of the V domains 
is critical in yielding the correct folding of the polypeptide chain. Previously, it has 
been estimated that the peptide linker must span 3.5 nm (35 Å) between the carboxyl 
terminus of the variable domain and the amino terminus of the other domain without 
affecting the ability of the domains to fold and form an intact antigen­binding site. In 
addition to the linker peptides designed de novo, peptide sequences derived from 
known protein structure have been applied to provide a compatible length and 
conformational in bridging the variable domains of a without serious steric 
interference. Apart from the length of the linker, their amino acid composition also 
plays an important role in the design of a viable linker peptide. They must have a 
hydrophilic sequence in order to avoid intercalation of the peptide within or between 
the variable domains throughout the protein folding. Nowadays, the most extensively 
used designs have sequences comprising stretches of Gly and Ser residues which 
meant for flexibility and or together with the charged residues such as Glu and Lys 
interspersed to enhance the solubility (Ahmad et al. 2012). 
 The scFv antibodies have been constructed mainly from hybridoma (Singh 
et al. 2010), spleen cells from immunized mice (Hayhurst et al. 2003, Wang et al. 
2006) and B lymphocytes from human (Reiche et al. 2002, Pansri et al. 2009). The 
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scFv is a non­covalent heterodimer comprised of the VH and VL domains (Skerra and 
Plückthun 1988). For producing, mRNA is first isolated from hybridoma (or also from 
the spleen, lymph cells, and bone morrow) followed by reverse transcribed into cDNA 
to serve as a template for antibody genes amplification (PCR). With this method, 
large libraries with a diverse range of antibody VH and VL genes could be created 
(Pansri et al. 2009). In the scFv construction, most of them are constructed in a VH­
linker­VL orientation (Ahmad et al. 2012).  One of the most popular methods used is 
through PCR assembly which was first described by Horton et al. (1990). In this 
method, it allows the V domains of antibody to be cloned without any prior 
information about the nucleic acid as well as amino acid sequence of the particular 
antibody. Moreover, the V domains of antibody can be combined by in vitro 
recombination directly after the PCR of VH and  VL genes into plasmid (Chaudhary 
et al. 1990) or phagemid (Ahmad et al. 2012). 
 Numerous scFv have been constructed against hapten (Kobayashi et al. 
2005), protein (Dai et al. 2003), carbohydrate (Ravn et al. 2004, Sakai et al. 2007), 
receptor (Galeffi et al. 2006), tumor antigen (Shadidi et al. 2001, He et al. 2002), and 
viruses (Griep et al. 2000, Hu et al. 2005, Saldarelli et al. 2005). All these scFv have 
good potential for use in many fields such as medical therapies and diagnostic 
applications. 
 Nowadays, scFv have been successfully isolated and displayed as 
fragments in various expression systems such as mammalian cell and yeast (Ho et al. 
2006), plant (Galeffi et al. 2006), and also insect cells (Choo et al. 2002). The scFv 
antibody can be expressed as correctly folded and directly active proteins or as 
aggregates requiring in vitro refolding to become active. Depending on the expression 
system, it varies in their ability to fold and secrete the scFv proteins. There are some 
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general regulations to consider on the design of vectors and expression system used 
with the different hosts and each of this host has advantages and disadvantages for the 
production of active antibody (Verma et al. 1998). Nevertheless, the bacterial 
expression system is most often applied for the production of scFv antibody fragments 
compared to the various expression strategies available (Frenzel et al. 2013). 
 
 2.3.3 Page display 
 2.3.3.1 Principle of phage display 
 Phage display was first described by George P. Smith in 1985, 
when he demonstrated the display of peptides on filamentous phage by fusing the 
peptide of interest on to gene III of filamentous phage (Smith 1985). Later, the 
technique was taken further by Greg Winter and John McCafferty at the Laboratory of 
Molecular Biology in Cambridge, UK, and Richard Lerner and Carlos F. Barbas at 
The Scripps Research institute, US, who independently used phage display to build 
large libraries of fully human antibody sequences. They have successfully 
demonstrated that a scFv fragment can be displayed on the phage surfaces as a 
functional protein which retains an active antigen­binding domain capability. This 
work laid the foundation for the development of human antibody based drugs  
(McCafferty et al. 1990). Therefore, this technology could allow rare clones to be 
screened and isolated from a large population of phage using any desirable antigen 
(Ahmad et al. 2012). Phage display is a laboratory platform that facilitates the study 
of protein to protein, protein to peptide, and protein to DNA interactions. Since its 
invention in 1985, phage display has been successfully applied to many different 
fields of research including immunology, cancer research, drug discovery, epitope 
mapping, protein­protein interactions, plant sciences, and infectious diseases, 
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targeting a broad cross­section of protein families. It has also been used to identify 
small peptide ligands and antibodies inhibiting the function of targeted receptors for a 
wide range of applications (Huang et al. 2012). Phage display is now playing a 
significant role for the discovery of peptides and antibodies that may serve as novel 
therapeutics (Nelson et al. 2010, Fjell et al. 2012). 
 Phage display involves the expression of peptides, proteins, or 
antibody fragment on the surface of filamentous bacteriophage. The interested DNA 
sequence is inserted into a location in the phage genome and fused to a gene encoding 
a phage coat protein. The interested protein is expressed or displayed on the surface of 
the phage particle, fused to one of the phage coat proteins. The phenotype of the 
expressed protein is thus linked to its genotype, which is present in the genome of the 
phage.  Using recombinant DNA technology collections of billions of peptides, 
protein variants, gene fragments or cDNA­encoded proteins presented on phage can 
be constructed and surveyed for specific affinity and activity (Bratkovic 2010). 
 
 2.3.3.2 Biology of the filamentous bacteriophage 
 Although T4, T7, and λ phage have been used for phage display, 
the most commonly used  phages are M13 and fd filamentous phage because they do 
not lyse infected bacteria during their life cycle (Huang et al. 2012). 
 Filamentous phages are a large family of bacterial viruses that 
infect many gram­negative bacteria by using the bacterial pili as a receptor. The most 
information about filamentous phages derives from those that infect E. coli: 
fl/M13/fd. They are usually referred to collectively, as Ff phages. These infect E. coli 
containing the F conjugative plasmid. The genomes of above three bacteriophages 
have been completely sequenced and are 98% homologous (Russel et al. 2004). 
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 Structure of the phage particle: The native particle of filamentous 
phages is a thin, cylindrical shape, approximately 7 nm wide and 900nm in length. 
They have a single­stranded DNA genome (6,407base pairs in length) which encodes 
11 genes (Carmen et al. 2002). The gene products are listed in Table 2.2 
 
Table 2.2 Genes and gene products of fl bacteriophage (Webster 1996). 
 
Gene 
 
Amino acid 
 
Function 
 
I 
 
Assembly 
 
348 
II DNA replication 410 
III Minor capsid protein 406 
IV Assembly 405 
V Binding of ssDNA 87 
VI Minor capsid protein 112 
VII Minor capsid protein 33 
VIII Major capsid protein 50 
IX Minor capsid protein 32 
X DNA replication 111 
XI Assembly 108 
 
 The genes are grouped in the genome according to their functions 
in the life cycle of the bacteriophage (Figure. 2). There are three groups of genes 
(Webster 1996). The first group encodes proteins required for DNA replication. They 
consist of three genes (II, V, X). The second group encodes the proteins which make 
up the capsid. They consist of five genes (III, VI, VII, VIII and IX). The third group 
encodes three proteins related in the membrane assembly of the phage. They consist 
of three genes (I, IX, XI) 
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Figure 2.2 The schematic structure of filamentous bacteriophage, the copy number 
of each protein is shown in brackets (Mullen et al. 2006). 
 
 Life cycle: The stages of a phage life cycle are infection, replication 
of the viral genome, assembly of new viral particles, and then release of the progeny 
particles from the host. During phage infection, the pIII end of the phage attaches to 
the F pilus of male E. coli. Then, the pVIII major capsid proteins and other capsid 
proteins integrate into the inner bacterial membrane. The phage ssDNA is translocated 
into the cytoplasm of bacteria. This process requires the presence of the bacterial 
TolQRA protein (Karlsson et al. 2003). Mutations in any one of these genes block the 
uptake of the phage DNA into the cytoplasm. After that, the circular single­stranded 
viral DNA (plus strand) is converted to a double­stranded replicative form (RF) using 
the host cell DNA replication mechanism. The RF is then used to express all of the 
viral genes. The viral gene II product nicks the plus strand of the RF to initiate 
replication. In the initial stages of viral infection the newly synthesized plus strands of 
circular single­stranded DNA are converted to the RF which is used for protein 
synthesis and DNA replication. In the latter stages the synthesized single­stranded 
DNA is bound by the viral gene V protein (gpV­DNA) for viral assembly. The five 
viral structural proteins are synthesized and inserted into the inner membrane of the 
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host cell. The phage­assembly process involves both the gene I protein and the gene 
IV protein which form a pore in the membrane of the host cell from which the viral 
particle is released. The gene VII proteins and the gene IX proteins are assembled 
first. The gene V protein in the gpV­DNA complex is replaced by gpVIII coat as the 
phage is extruded from the host cell. Finally, the gene VI protein is assembled 
followed by gpIII, which terminates phage assembly (Webster 1996, Adda et al. 
2002). 
 
 
Figure 2.3 Life cycle of filamentous phage. Filamentous phage binds to the F pilus 
of a host bacteria cell thorough pIII. Then the host TolA protein starts to 
depolymerize the phage coat, which remain in the inner membrane for 
recycling.  The ssDNA of the phage enters into the cytoplasma, converts 
into dsDNA and starts replication and expression using host enzymes, 
ssDNA and coated pV protein dimers form the precursors of the phage. 
Then pV is replaced by pIII in the chanel formed by pI, pXI, pIV and the 
host thioredoxin; in the meantime, mature phage particles are 
assemblyed and released (Russel et al. 2004, Huang et al. 2012). 
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 2.3.3.3 Phage display vectors and types of phage display systems 
 Phagemids are Ff­phage­derived vectors, containing the replication 
origin of a plasmid. The basic components of a phagemid mainly include the 
replication origin of a plasmid, the selective marker, the intergenic region (IG region, 
usually contains the packing sequence and replication origin of minus and plus 
strands, a gene of a phage coat protein, restriction enzyme recognition sites, a 
promoter and a DNA segment encoding a signal peptide (Azzazy and Highsmith 
2002, Qi et al. 2012). Moreover, phagemids often contain an amber stop codon, to 
allow host specific expression of pIII fusion protein or soluble fusion partner 
(Hoogenboom et al. 1991) and a gene encoding one coat protein that will be fused to 
the foreign DNA that is to be expressed (Barbas et al. 1991, Kang et al. 1991). 
 Phagemids can maintain themselves as plasmids, resulting in the 
expression of the desired protein in the bacteria. However, they lack other genes that 
encode proteins necessary for assembly of phage particle. To get production of viable 
phage, an infection with a helper phage is necessary. The helper phage provides the 
genes for the phage proteins that are missing on the phagemid. The packing signal in 
the helper phage genome has been altered to be less effective, and thus the 
recombinant ssDNA of phagemid is packaged into phage particles using helper phage 
proteins (Bass et al. 1990). 
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Figure 2.4 Phagemid display vector. A “typical” phagemid display vector contains 
origins of replication for double­stranded DNA and ssDNA synthesis 
(plasmid and filamentous phage origins), an antibiotic resistance gene 
providing selection of transformed bacteria and a fusion gene under the 
control of a regulated promoter (Qi et al. 2012). 
 
 There are many different types of phage­display libraries. In most 
cases the recombinant protein is expressed on either gpIII or gpVIII referred to as the 
type 3 and type 8 libraries respectively (Smith and Petrenco.P.A. 1997, Adda et al. 
2002).  There are three general classes of phage display systems. The first is based on 
the natural filamentous phage genome, the ssDNA vector. Libraries constructed by 
introducing foreign DNA inserts into the phage genome will result in the fusion gene 
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product displayed on all the coat proteins. The second system entails the use of 
plasmid vectors, also known as phagemids. Third, a “hybrid system,” which still 
utilizes the phage genome but which contains both a wide­type phage gene and a 
fusion gene, can be employed (Huang et al. 2012). To distinguish between these 
systems based on the expressed protein, Smith coined the terms “3,” “3 3,” and “33,” 
respectively (Smith and Petrenco.P.A. 1997). In the type 3 libraries, a gene insert 
encoding the recombinant protein can be included as a fusion fragment within the 
phage genome such that all copies of gpIII are expressed as a chimera with the foreign 
protein. Alternatively, if the phage genome contains genes for both the wild type and 
recombinant gpIII, then a mixture of recombinant and wild type gpIII molecules are 
produced and incorporated into the viral particles. This system is referred to as type 
33.When the foreign protein is large, as in the case of antibody libraries, the gene 
sequence encoding recombinant gpIII is contained on a phagemid within the phage 
particle.  Helper phage which contain a defective origin of replication, are used to 
produce the wild type phage proteins, such that the resulting phage particle contains 
the phagemid DNA and variable (ie. 0 ­ 5) copies of the recombinant gpIII molecule. 
These are referred to as the type 3+3 libraries. A series of random peptide libraries 
displayed on gene VIII, referred to as type 8 libraries are also available. These parallel 
the type 3 libraries in that they include types 8, 88 and 8+8 (Smith and Petrenco.P.A. 
1997, Bratkovic 2010). 
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Figure 2.5 Types  of phage display systems (Smith and Petrenco.P.A. 1997). 
 
 2.3.3.4 Selection of antibody libraries: “bio-panning” 
 Antibody libraries are screened and enriched for antigen­specific 
clones by a technique known as bio­panning in which phages displaying scFv are 
incubated with an immobilized antigen of interest (Nissim et al. 1994). A selection 
cycle basically contains four stages: (i) incubation of target molecules with a phage 
display library, (ii) washing off unbound phage, (iii) elution of the bound phage, and 
(iv) amplification of the eluted phage. This selection cycle is illustrated in Figure 6. 
Ideally, only one cycle of selection should be required, however the binding of 
nonspecific phage limits the enrichment that can be achieved per cycle. In practice, 
several rounds of selection are necessary (average 2­4 cycles). Several biopanning 
strategies are discussed below. 
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Figure 2.6 Biopanning of a phage display library to select phage binding to an 
immobilized target (Huang et al. 2012). 
 
 Although the principle of biopanning technique is simple, the 
outcome can vary due to multiple factors, such as library complexity, nature of the 
target, binding affinity and avidity, and other multiple experimental parameters. Even 
with an excellent selection strategy, the experiment will fail if the desired 
peptide/antibody is not present in the library. Binding affinity and avidity are other 
factors that need to be taken into consideration (Huang et al. 2012). 
 Selection using immobilized antigens: Phage libraries are selected 
by flowing through an affinity column with the immobilized antigen of interest 
(Clackson et al. 1991). Following washing of the column to remove nonspecific 
clones, specific binders are eluted and amplified in E. coli. Selection can also be 
performed against antigen adsorbed onto plastic surfaces such as immunotubes or 
enzyme­linked immunosorbent assay (ELISA) plates (Marks et al. 1991). 
34 
 
Alternatively, antigen may be immobilized on chips of BIAcore sensors (Malmborg et 
al. 1996). 
 It should be noted that selection of the immobilization method must 
take into consideration the conformational integrity of the immobilized antigen. Some 
phage antibodies selected against an adsorbed antigen may not be able to recognize 
the native form of the antigen. One way to circumvent such problem is to employ 
indirect antigen coating through the use of antigen­specific capture antibodies (Sanna 
et al. 1995). 
 
 Selection using antigens in solution: This technique allows solution 
binding and overcomes issues with conformational changes that are encountered upon 
coating antigens on solid surfaces. The use of labeled soluble antigens also allows a 
more accurate quantification of the antigen used during selection and consequently 
enhances the ability to use lower concentrations of the antigen to favor selection of 
high­affinity phage antibodies. Following incubation of phage­antibodies with 
biotinylated antigen, phage bound to the labeled antigen are recovered with avidin or 
streptavidin­coated paramagnetic beads. Specific phages are then dissociated from the 
antigen and characterized (Hawkins et al. 1992). One disadvantages of this technique 
is that antistreptavidin antibodies will also be isolated. However, this problem can be 
resolved by a depletion step using streptavidin­coated beads (Azzazy and Highsmith 
2002). 
 
 Selection on whole cells: Direct selection of antibodies against 
markers on cell surfaces may be carried out on either monolayers of adherent cells or 
on cells in suspension. Unbound phage can be washed away by rinsing tissue culture 
flasks (monolayers) or centrifugation (cell suspension). To optimize the isolation of 
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antigen­specific binders and minimize the binding of irrelevant binders, a 
simultaneous positive and negative selection may be applied. In this approach, a 
competition is set up between a small number of antigen­positive target cells and an 
excess of antigen­negative “absorber” cells to bind antibodies of phage library; the 
absorber cells serve as a sink for the nonspecific adherence of irrelevant binders. A 
fluorescently labeled antibody against an irrelevant antigen present only on the target 
cells is added and FACS (Fluorescence­activated cell sorting) is used to isolate the 
target cells binding the specific phage antibodies (de Kruif et al. 1995). Similar 
approaches can be utilized to identify putative tumor­specific antigens and provide a 
quick high­yield approach for isolating self­replicative antibody fragments directed 
against novel or conformationally dependent cell surface markers. Another group 
subjected a scFv library to three rounds of positive selection on human melanoma 
cells and negative selection on human peripheral blood mononuclear cells (Kupsch et 
al. 1999). Selections may also be carried out on tissue sections as well as whole 
tissues (Azzazy and Highsmith 2002). 
 The advantages of whole­cell phage display are easy to see. In the 
case of when antigen is unavailable or the antigen is not stable under immobilization 
conditions, whole­cell phage display panning is normally the best choice. In addition, 
it is also useful in the discovery of unknown antigens. The biopanning procedure 
typically requires no prior knowledge of the cell surface biomarkers, allowing for the 
isolation of targeting peptides for cell types for which little is known about the 
cellular profile. For whole­cell screening, the cellular targets are identified in a two­
part process. First, peptides or antibodies are first identified by screening whole cells 
against a phage display library. Second, the binding peptides or antibodies are tested 
individually in functionally based screens. In all cases, activity is confirmed in 
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functional assays; one does not need to either purify or identify a particular receptor in 
advance. Since whole cells are used as the affinity matrix, the receptors are likely to 
be in their native conformation, and a large variety of receptors are being screened at 
one time. It should be noticed that the cell surfaces would share a high degree of 
similarity and that the peptides would be recognizing abundant, common receptors. 
Thus, additional negative selections are necessary to avoid unexpected cell specificity 
of selected peptides (Huang et al. 2012). 
 
 The in vivo selection: In this method phage repertoires are directly 
injected into animals and then tissues are collected and examined for phage bound to 
tissue­specific endothelial cell markers as was demonstrated for peptide phage. 
Pasqualini et al. (1996) were the first to isolate phage­displayed peptides that home to 
selective vascular beds in vivo. In vivo panning has several advantages: (i) the isolated 
phage­displayed peptides home selectively to “intact” targets of interest; (ii) an 
inherent blocking step is included where most of the phage­displayed peptides that 
recognize ubiquitous plasma and cell surface proteins are eliminated; (iii) these 
peptides may be useful for the functional analysis of new receptors and potential 
identification of novel drug target candidates because some of the isolated peptides 
have been found to bind to endothelial receptors expressed in the vasculature of 
specific tissues. 
 
 2.3.3.5 Application of phage display 
 Applications for phage-displayed peptide libraries: Phage display 
of random peptides:  Synthetic oligonucleotides with a constant length but with 
unspecified codons, randomized through site­directed mutagenesis using degenerate 
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oligodeoxynucleotides, are cloned as fusions to one of the coat proteins of M13 phage 
where they are expressed as peptide­capsid fusion proteins (Azzazy and Highsmith 
2002). Phage­displayed peptide libraries can be used to isolate peptides that bind with 
high specificity and affinity to virtually any target protein. These binding peptides can 
be used as reagents to understand molecular recognition, as minimized mimics for 
receptors, or as lead molecules in drug design (Sidhu 2000). 
 Mapping antibody epitopes: Fragments of DNA that encode parts 
of the protein antigen are fused to a gene encoding one of the capsid proteins. Phage 
particles displaying antigenic peptides can be used for mapping epitopes of 
monoclonal and polyclonal antibodies (Hill et al. 1996). Phage display libraries of 
random peptides have also proven useful for identifying antibody epitopes in cases in 
which the antigen is not available or even not yet known (Cortese et al. 1994). 
  
 Phage-antibody applications: Phage­displayed recombinant 
antibodies have several advantages over monoclonal antibodies generated by 
hybridoma technology. In comparison to the time­consuming and labor­intensive cell 
screening processes of hybridoma production, antibody genes can be cloned directly 
from spleen cells using rapid recombinant DNA methods. Generation of a large 
natural display library from variable gene repertoires can eliminate animal 
immunization and large­scale cell culture for hybridoma development and allow 
isolation of antibodies with high affinity against any antigen. Phage display is 
particularly useful in cases where monoclonal antibodies could not be obtained by 
classical hybridoma technique such as antibodies against nonimmunogenic or toxic 
antigens. Phage displayed antibodies have stable genetic source. Phage antibody 
technology can also be used to clone and rescue monoclonal antibodies from 
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genetically unstable hybridomas. Phage antibody genes can be easily sequenced, 
mutated, and screened to improve antigen binding. Finally, soluble recombinant 
antibodies (not displayed on phage) can be produced quickly and economically and 
can be used as in vitro diagnostic reagents (Azzazy and Highsmith 2002). 
 Phage display has been used widely for identification of specific 
antibodies against pathogen targets. These targets are generally subdivided into two 
categories: (i) molecular targets, such as replication/cell division enzymes and host­
pathogen virulence factors, and (ii) whole bacterial cells. In comparison with specific 
molecular targets, cell­based screening has the advantage in that it is an assumption­
free strategy with the potential to recognize cell surface structures that may not have 
been considered targets using genomic­based approaches or that have not yet been 
identified. Using live pathogens as the target also has the advantage that all 
“druggable” targets on the cell surface are screened simultaneously in their native 
physiological context, thus allowing for the selection of potential antimicrobial 
activity from the outset. Antigens on the cell surface of pathogens are appealing 
targets for biologics because they provide potential binding sites for molecules to 
interfere with bacterial division (Lock et al. 2008) colonization, and virulence (Rasko 
et al. 2010). Both strategies have been widely applied for developing novel diagnostic 
tools and therapeutic treatments for infectious diseases (Huang et al. 2012). 
 Phage enzymes: Several enzymes have been displayed on M13 
bacteriophages and retained their catalytic activities. These include alkaline 
phosphatase (McCafferty et al. 1991), trypsin (Corey et al. 1993), and β­lactamase 
(Siemers et al. 1996). In theory, any enzyme that can be expressed in E. coli may also 
be displayed on M13 phage. 
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 Phage display libraries based on suitable enzymes can improve 
diagnostics by enhancing the stability and catalytic activities of enzymes, and 
probably enabling the engineering of catalysis that is modifiable by antigen binding. 
 
 Application of phage display technology in detection and 
monitoring of microorganisms: Conventional bacterial detection, diagnostic methods, 
especially pathogenic bacteria and virus, largely rely on microbiological and 
biochemical analysis which can be sensitive but overly time consuming, cost­
ineffective and non­amenable to integration for on­site diagnosis. 
 Today, phage display is recognized as a powerful tool for selecting 
novel peptides and antibodies that can bind to a wide range of antigens, ranging from 
whole cells to proteins and lipid targets. Phage display has been used widely for 
identiﬁcation of speciﬁc peptides and antibodies against pathogen targets. These 
targets are generally subdivided into two categories: (i) molecular targets, such as 
replication/cell division enzymes and host­pathogen virulence factors, and (ii) whole 
bacterial cells. Both strategies have been widely applied for developing novel 
diagnostic tools and therapeutic treatments for infectious diseases. (Huang et al. 
2012). 
 Staphylococcus aureus, one of the most important human 
pathogens, has become a major threat to human health.  Soykut et al. (2008) has used 
a peptide­phage display library to identify peptides binding to Staphylococcal 
enterotoxin B produced by S. aureus, is a pyrogenic toxin responsible for 
staphylococcal food poisoning in humans and has been an attractive choice of 
biological aerosol weapon due to its inherent stability and high intoxication effect. 
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 Listeria monocytogenes is a severe food­borne pathogen that 
causes life­threatening listeriosis. To avoid infection by L. monocytogenes, it is 
important to detect low levels of the pathogen in food samples. Paoli and colleagues 
used phage display to identify a scFv antibody that can only bind to L. monocytogenes 
(Paoli et al. 2004). Later, in 2007, a surface plasmon resonance (SPR) sensor was 
developed based on the scFv antibody by Nanduri et al. (2007). L. monocytogenes­
specific scFv­displayed phage was immobilized on the sensor surface to detect L. 
monocytogenes at a detection limit of 2x106 CFU/ml. The some results about 
application of phage display technique in detection of microorganisms were 
summarized in Table 2.3 
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Table 2.3 The phage display targets of some microorganisms. 
 
Target 
 
Library 
 
Potential application 
 
Reference 
 
Molecule target 
     SEB (staphylococcal enterotoxin B) 
     SEB (staphylococcal enterotoxin B) 
     Staphylococcal enterotoxin A and B 
     Surface layer protein of Campylobacter fetus 
     Lipopolysaccharide (LPS) of Ralstonia 
solanacearum 
     Clostridium difficile toxin B 
     Plasmodium vivax duffy binding protein 
     S. aureus SdrC 
     P. aeruginosa MurA 
     P. aeruginosa MurC 
     Esp and Intimin of Escherichia coli O157:H7 
     Intimin virulence of Escherichia coli 
     Surface epitopes of Phytophthora infestans 
     Bhlp 29.7 protein of Brachyspora 
hyodysenteriae 
     Fumonisin B1 of Fusarium verticillioides 
     H. pylori surface protein 
     Cell wall­bound proteins of  Fusarium  
verticillioides 
     Cell wall­bound proteins of Aspergillus flavus 
     σ 54 factor of Pseudomonas putida 
     Liposaccharide/lipid A 
 
     Lipopolysaccharide (LPS) of Burkholderia 
mallei 
     SapA protein of Campylobacter fetus 
     Protective antigen of Bacillus anthracis 
 
     HrpA of Pseudomonas syringae 
     Botulinum neurotoxin A light chain 
 
 
12­mer peptide library 
ScFv library 
ScFv library 
peptide library 
 
ScFv library 
ScFv library 
ScFv library 
12­mer peptide library 
C7C cyclic peptide, 12­mer peptide library 
C7C cyclic peptide, 12­mer peptide library 
ScFv library 
ScFv library 
ScFv library 
ScFv library 
 
ScFv library 
ScFv library 
ScFv library 
 
ScFv library 
ScFv library 
ScFv libraries, peptide libraries 
 
ScFv libraries 
 
Peptide libraries 
ScFv libraries 
 
ScFv library 
ScFv libraries 
 
 
Anti­S. aureus 
Anti­S. aureus 
Diagnosis 
Anti­C. fetus 
 
Diagnosis 
Diagnosis 
Diagnostics, vaccine design 
Anti­S. aureus 
Anti­P. aeruginosa 
Anti­P. aeruginosa 
Diagnosis 
Diagnosis 
Diagnosis 
Diagnosis 
 
Detection 
Anti­H. pylori 
Detection of Fusarium 
verticillioides 
Detection of Aspergillus flavus 
Detection 
Anti­Gram­negative bacterial 
agents 
Detection of Burkholderia 
mallei 
Detection 
Detection of Bacillus 
anthracis 
Diagnosis 
Anti­botulinum neurotoxin 
 
 
(Soykut et al. 2008) 
(Singh et al. 2010) 
(Liang et al. 2011) 
(Zhao et al. 2012) 
 
(Griep et al. 1998) 
(Deng et al. 2003) 
(Kim et al. 2007) 
(Barbu et al. 2010) 
(Molina­Lopez et al. 2006) 
(El Zoeiby et al. 2003) 
(Kühne et al. 2004) 
(Menezes et al. 2011) 
(Gough et al. 1999) 
(Lobová et al. 2008) 
 
(Lauer et al. 2005) 
(Cao et al. 2000) 
(Hu et al. 2013) 
 
(Xue et al. 2013) 
(Jurado et al. 2012) 
(Griep et al. 1998, Hayhurst 
et al. 2003) 
(Kim et al. 2011) 
 
(Zhao et al. 2012) 
(Wang et al. 2006) 
 
(Yang et al. 2013) 
(Miethe et al. 2014) 
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Table 2.3 (Continued). 
 
Target 
 
Library 
 
Potential application 
 
Reference 
 
     Capsular of Burkholderia pseudomallei 
      
     Pseudonitzchia pungens toxin domoic acid 
     Crf antigen of Aspergillus fumigatus 
     OmpD of Salmonella Typhimurium 
     Shiga toxins (Stxs) of Escherichia coli 
     Ts1 toxin from Tityus serrulatus 
     Staphylococcal enterotoxins of Staphylococcus 
aureus 
     Plasmodium falciparum histidine rich protein 2 
     Toxoplasma gondii MIC2 protein 
     Hepatitis C virus proteins 
 
     Hepatitis A virus antibodies 
     Hepatitis E virus capsid protein 
     Phosphoprotein of Newcastle disease virus 
     H5N1 HA 
     Transmembrane envelope glycoprotein gp46 of 
maedi­visna virus 
     p25 protein of the Maedi­Visna virus 
     Eimeria acervulina surface antigen 
 
     Vesicular stomatitis virus (VSV) nucleocapsid 
     E protein and N protein of severe acute 
respiratory syndrome virus 
     CoV spike protein of severe acute respiratory 
syndrome virus 
 
     Porcine reproductive and respiratory syndrome 
virus­N protein 
     VP2 protein of infectious bursal disease virus 
     S Protein of porcine epidemic diarrhea virus 
 
ScFv libraries 
 
ScFv libraries 
ScFv library 
ScFv library 
ScFv library 
ScFv library 
ScFv library 
 
ScFv library 
ScFv library 
ScFv libraries, peptide libraries 
 
9­mer peptide library 
Antibody library 
ScFv libraries 
Fab library 
ScFv libraries 
 
ScFv libraries 
ScFv libraries 
 
ScFv libraries 
ScFv libraries 
 
ScFv libraries 
 
 
12­mer peptide library 
 
ScFv libraries 
scFv libraries 
 
Detection of Burkholderia 
pseudomallei 
Anti­toxin domoic acid 
Diagnosis 
Diagnosis 
Diagnosis 
Anti­scorpion 
Anti­toxin 
 
Diagnosis 
Against parasite antigens 
Diagnostics, vaccine design 
 
Diagnostics 
Anti­HEV infection 
Anti­virus 
Anti­H5N1 infection 
Diagnosis 
 
Diagnosis 
Diagnostics, vaccine design 
 
Diagnosis 
Diagnosis 
 
Diagnosis 
 
 
Detection of PRRSV 
 
Diagnosis 
Diagnosis 
 
(Kim et al. 2011) 
 
(Finlay et al. 2006) 
(Schütte et al. 2009) 
(Meyer et al. 2011) 
(Neri et al. 2011) 
(Amaro et al. 2011) 
(Chen et al. 2014) 
 
(Leow et al. 2014) 
(Hoe et al. 2005) 
(Bugli et al. 2001, Bugli et 
al. 2009) 
(Larralde et al. 2007) 
(Schofield et al. 2000) 
(Li et al. 2014) 
(Lim et al. 2008) 
(Blazek et al. 2004) 
 
(Celer et al. 2003) 
(Kim et al. 2001, Park et al. 
2005) 
(Cortay et al. 2006) 
(Liu et al. 2004) 
 
(Lee, Leu, Hu, et al. 2007, 
Lee, Leu, Hung, et al. 2007, 
Zhao et al. 2007) 
(Ren et al. 2010) 
 
(Xu et al. 2014) 
(Zhu et al. 2013) 
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Table 2.3 (Continued). 
 
Target 
 
Library 
 
Potential application 
 
Reference 
 
Whole cell target 
     L. monocytogenes 
      
     P. aeruginosa 
     H. pylori 
     Eimeria acervulina merozoite 
     Neisseria meningitides group B 
     Lawsonia intracellularis 
     S. typhimurium 
     Burkholderia mallei 
     Ceratitis capitata 
     Fusarium verticillioides 
     Brucella melitensis 
     Plasmodium falciparum 
     Spores of Bacillus 
 
 
 
     Venezuelan equine encephalitis virus 
(VEEV) 
     Chlamydia trachomatis EBs 
     Eimeria acervulina merozoite 
     Grapevine virus B 
     Tomato spotted wilt virus 
     Infectious haematopoietic necrosis 
virus 
     Foot and mouth disease virus 
     Rabies virus 
     Virulent infectious bursal disease virus 
 
     Severe acute respiratory syndrome 
virus 
 
 
ScFv library 
 
9­mer peptide, 12­mer peptide 
ScFv library 
ScFv library 
ScFv library 
ScFv library 
8­mer peptide library 
ScFv libraries 
ScFv libraries 
ScFv libraries 
ScFv libraries 
ScFv libraries 
ScFv libraries, peptide libraries 
 
 
 
ScFv library 
 
ScFv library 
ScFv library 
ScFv library 
ScFv library 
ScFv library 
 
ScFv library 
scFv library 
scFv library 
 
scFv library 
 
 
Diagnostics of L. monocytogenes 
infection 
Diagnostics of P. aeruginosa infection 
Diagnostics of H. pylori infection 
Diagnostics, vaccine design 
Diagnosis 
Diagnosis 
Diagnostics of S. Typhimurium 
Detection of Burkholderia mallei 
Detection of C.capitata 
Detection 
Diagnosis 
Diagnosis 
Detection of Bacillus species 
 
 
 
Detection of VEEV infection 
 
Detection of C. trachomatis 
Detection of Eimeria acervulina 
Detection of virus 
Detection of virus 
Detection of virus 
 
Detection of virus 
Anti­virus 
Detection of virus 
 
Detection of virus 
 
 
(Nanduri et al. 2007) 
 
(Carnazza et al. 2008) 
(Sabarth et al. 2005) 
(Zhao et al. 2010) 
(Stacy et al. 2003) 
(Dezorzová­Tomanová et al. 2007) 
(Sorokulova et al. 2005) 
(Zou et al. 2007) 
(Monzó et al. 2012) 
(Hu et al. 2013) 
(Hayhurst et al. 2003) 
(Wajanarogana et al. 2006) 
(Zhou et al. 2002, Knurr et al. 2003, 
Turnbough 2003, Williams et al. 2003, 
Brigati et al. 2004, Mechaly et al. 2008, 
Walper et al. 2012) 
(Kirsch et al. 2008) 
 
(Lindquist et al. 2002) 
(Zhao et al. 2010) 
(Saldarelli et al. 2005) 
(Griep et al. 2000) 
(Liu et al. 2014) 
 
(ShengFeng et al. 2003) 
(Pruksametanan et al. 2012) 
(Sapats et al. 2003, Sapats et al. 2005, 
Sapats et al. 2006) 
(Liu et al. 2005) 43 
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CHAPTER III 
MATERIALS AND METHODS 
 
3.1 Materials 
All chemical reagents are molecular biology grade. Yamo1, a human non­
immunized ScFv library, was constructed in laboratory using B­lymphocytes from 
140 healthy people in the Northeastern Thailand (Pansri et al. 2009).  Escherichia coli 
TG1 [(lac-proAB) Sup E thi hrd D5/F’ tra D36 pro A
+
B lacI
q
 lacZΔM15] and 
HB2151 [K12 ara (lac-proAB) thi/F’proA
+
B lacI
q
 lacZΔM15] was obtained from the 
MRC, Cambridge, UK, and used for cloning and amplification of phage, or 
production of soluble ScFv fragments, respectively. The anti­M13/HRP detection kit 
was purchased from Amersham­Pharmacia Biotech (Uppsala, Sweden) and Protein L 
peroxidase HRP will be from Sigma. Bradyrhizobium sp. DOA9 was isolated from A. 
americana L. in Thailand in our laboratory (Noisangiam et al. 2012). 
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3.2 Instruments 
These are all instruments that we used in this work. 
 
Table 3.1 Instruments and brands. 
 
Instrument 
 
Brand 
 
Autoclave 
 
Hiclave HA­3000MIV, Hirayama, Japan 
Balance Precisa 205A, Precisa Instruments, Switzerland 
Precisa 3000C, Precisa Instruments, Switzerland 
Centrifuge machine Sorvall RC5C plus, Kendro laboratory Products, USA 
Eppendrof centrifuge 5810 R, Eppendrof, USA 
Deep freezer ­70 OC Heto, Ultra Freeze, Denmark 
ELISA reader Sunrise, TECAN, Austria 
Electroporator Eppendrof 2510, Eppendrof, USA 
Freezer ­20 OC Heto, HLLF 370, Denmark 
MyBio LFT420, DAIREI, Denmark 
Gel Document set White/Ultraviolet Transilluminator GDS7500, UVP, USA 
Digital Graphic Printer UP­D890, Sony, Japan 
Gel dryer Drygel sr. SLAB GEL Dryer model SE1160, Hoefer 
Scientific Instruments, USA 
Gel electrophoresis apparatus Mini Protean® 3 cell, BioRad, USA 
Heat Box HB1, Wealtee Corp., USA 
Incubator shaker C24 Incubator shaker, New Brunswick Scientific, USA 
Incubator Memmert, BE 500, WTB Binder BD115, Shel­Lab 2020 
Low Temperature Incubator, Sheidon, USA 
Laminar hood Holten LaminAir HBB 2448, Denmark 
BH2000 Series ClassII Biological Safety Cabinets 
BHA120 & BHA180, Clyde­Apac 
Membrane transfer machine Semi Phor, Hoefer Scientific instruments, USA 
46 
 
 
 
 
Table 3.1 (Continued). 
 
Instrument 
 
Brand 
 
Microcentrifuge 
 
Mini spin plus, Eppendrof, USA 
Eppendorf 54154, Eppendorf, Germany 
pH meter Ultra Basic pH meter, Denver Instruments, Germany 
PCR machine DNA Engine PTC 200 peltier Thermal cycler, MJ Research, 
USA 
Rotator Certomat TCC, B. Braun Biotech International, Germany 
Sequencing machine ABI prism model 310 Genetic Analyzer, Applied Biosystems, 
USA 
Shaker Innova 2300 platform shaker, New Brunswick Scientific, UK 
Certomat TC2, B. Braun Biotech International, Germany 
Sonicator Waken GE100 Ultrasonic processor, Japan 
Spectrophotometer Ultrospec 2000, Pharmacia biotech, UK 
Stirrer Variomag Electronicrührer Poly 15, Germany 
Magnetic stirrer MSH300, USA 
Thermomixer Thermomixer compact, Eppendrof, USA 
Vortex Vortex­Genie 2 G506, Scientific Industries, USA 
 
3.3 Methods 
 3.3.1 Rabbit immunization with Bradyrhizobium sp. DOA9 
 3.3.1.1 Antigen preparation 
 Rabbits were selected for immunization. Rabbit antiserum was 
developed against Bradyrhizobium sp. DOA9 as described previously (Somasegaran 
and Hoben 1994).  The Bradyrhizobium sp. DOA9 strain was cultured in yeast 
mannitol medium flask in 28°C and 250 rpm for 5­7 days (Hoben et al. 1994). Cells 
were centrifuged at 4500 rpm at 4°C in 10 minutes and discarded supernatant. The 
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pellet was re­suspended in sterilized saline buffer by using a vortex mixer. The cell 
concentration was adjusted to approximately 1×109 cells ml­1 by diluting with saline 
buffer. Then, the cell suspension was boiling for 1 h at 100°C to inactivate any 
remaining flagella antigens. The merthiolate was added to achieve a final 
concentration of 1:10,000 as a preservation. The stock solution was stored at ­20°C 
until use (Somasegaran and Hoben 1994). 
 
 3.3.1.2 Immunization and antisera development 
 The healthy, young rabbit (6­12 months) was used for antiserum 
development. Three rabbits were used for the development of each antiserum. The 
rabbit was immunized by ear (intravenous) injections. The rabbit was rolled in a large 
towel, tightly securing the fore and rear limbs. The vein of rabbit was exposed by 
shaving a small section of the ear with a razor blade. Swab the shaved area with 
alcohol (70%) and inject the antigen with a syringe fitted with a narrow (25 gauge) 
needle (Somasegaran and Hoben 1994). The schedules for immunization were done 
following the schedule (Table 3.2). 
 
Table 3.2 The schedule of immunization of rabbit (Somasegaran and Hoben 1994). 
 
Day 
 
Method 
 
Antigen 
 
1 
 
intravenously (IV) 
 
0.5 ml working solution (WS) 
2 IV 0.5 ml WS 
3 IV 1.0 ml WS 
4 IV 1.5 ml WS 
5 IV 2.0 ml WS 
6­12 Resting  
13 Test bleed and perform agglutination titer  
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 3.3.1.3 Trial bleeding for titer determination 
 Blood was first bleed from intravenous (3­5 ml) to test the titer 
prior to get more blood by cardiac puncture. The rabbit was tied to the inclining 
bleeding rack. The area above the sternum was sterilized with 70% alcohol. The blood 
was drawn from heart with a 50­ml syringe equipped with a 26­gauge needle. Collect 
20­30 ml of blood in a test tube. Then, the blood was centrifuged at 4500 rpm in 10 
minutes. The supernatant was transferred into the new sterile tube and stored in ­200C 
(Somasegaran and Hoben 1994). The titer of serum was determined by the 
agglutination method (Somasegaran and Hoben 1994). 
 
 3.3.1.4 Agglutination method 
 Firstly, the stock antiserum was diluted as follows: Arrange 10 test 
tubes (16×125 mm) in a row on a test­tube rack. Label them 1 through 10. Then, 9.6 
ml of saline buffer was added into tube 1. For tubes 2­10, adding 2.5 ml of saline 
buffer. Accurately pipette 0.4 ml of the stock antiserum into tube 1. Mix the saline 
and serum thoroughly by sucking the serum­saline mixture into the pipette and then 
expelling the contents. This process will be repeated five times. Expelling should be 
done gently to avoid frothing. This tube now contains anti­serum of a 1/25 dilution. 
After that, 2.5 ml of diluted serum from tube 1 was transferred to tube 2, then mix 
well by using a fresh pipette (the dilution of the serum in tube 2 became 1/25×1/2 = 
1/50). The dilution was repeated successively from the previous tube to the next until 
reaching tube 10 by using a fresh pipette tip each time. 
 Performing agglutinations in microtiter tray: The process was 
started with the highest dilution (tube 10). The 500 µl of diluted antiserum were 
transferred from tube into well A10 of the plastic agglutination tray by using a clean 
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pipette. Then, the process was repeated until all the dilutions of the antiserum were 
dispensed into the respective wells of row A of the agglutination tray. After that, the 
500 µl of the homologous antigen (approximately 1×109 cells ml­1) were dispensed 
into each of the wells from well Al through A10 by using pipette. Then, the 500µl of 
serum of 1/25 dilution were transferred into well A11 and then 500 µl of saline were 
added into this well with another calibrated Pasteur pipette.  This serves as the serum­
saline control. Next, the 500µl of saline were placed into well A12 and then the 500 
µl of antigen were also added into this well. This serves as the antigen­saline control. 
All wells (Al through A12) were sealed with a strip of cellophane tape. The 
agglutination tray was placed in a water bath at 37°C for 2 h and then transferred to a 
refrigerator before reading the reactions. Figure 7 shows the steps for the antiserum 
titer determination in wells. The highest dilution of the serum for positive 
agglutinations was read and recorded. Positive agglutination appeared as granular 
clumps with clear supernatant. Negative agglutinations were indicated by cells 
settling on the bottom of the well and turbid supernatant. 
 To calculate the titer (serum titer is the reciprocal of the highest 
serum dilution at which positive agglutination occurs). The highest dilution of the 
serum that has positive agglutination was multiplied by two. This is because equal 
volumes of the diluted serum and antigen were titrated in the well. Example: If 
positive agglutination was detected at 1/3200 dilution of the serum, the true titer will 
be 3200×2 = 6400 (Figure 3.1). 
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Figure 3.1 Scheme for antiserum titer determination in wells (Somasegaran and 
Hoben 1994). 
 
 Collecting blood and giving booster injections: Once the titer was 
satisfactory (not less than 1:1600), blood was transferred into a sterile screw­cap test 
tube of 50­ml capacity. After the blood has been clotted and refrigerated, decant the 
serum and centrifuge at 5000×g for 15 min to clear the serum of red blood cells. 
Transfer the clear serum supernatant into an appropriate container for storage by 
freezing. Serum was stored in in suitable­sized vials. If the titer was too low in the 
trial bleeding (less than 1:1600), give a booster injection of 1 ml of antigen 
subcutaneously immediately after the titer determination (Somasegaran and Hoben 
1994). This serum was used as polyclonal antibody against Bradyrhizobium sp. 
DOA9 to compare with antibody derived from other methods. 
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 3.3.2 Phage display library construction from immunized rabbit 
 3.3.2.1 Isolation of total RNA from rabbit spleen cells 
 Seven days after the last boost, spleen cells from immunized rabbit 
with strain DOA9 were prepared for mRNA extraction. Total RNA was extracted 
from spleen cell by TRIzol reagent (Invitrogen, USA) according to the manufacturer’s 
protocol. The spleen was cut roughly up into small pieces with sterile scissors in a 
sterile Petri dish under liquid nitrogen, and the pieces were transferred into a sterile 
small mortar. Then, 1 ml of Trizol reagents were added into the mortar. The spleen 
tissues were homogenized with pestle under liquid nitrogen. After that, the 
homogenized solution was transferred to a 1.5 ml tube and 0.1 ml of chloroform was 
added.  After shaking vigorously for 15 seconds, the homogenized solution was 
centrifuged at 13000 rpm at 4ºC for 15 min. Then, the clear aqueous upper layer was 
carefully pipetted off from the lower organic layer, and the upper layer was 
transferred to a fresh tube. An equal volume of isopropanol was added to the tube. 
The tube was incubated at room temperature for 10 minutes. The precipitated RNA 
was pelleted by centrifugation at 13000 rpm for 15 minutes at 4°C. The pellet was 
washed with 0.5 ml of 75% ethanol and then centrifuged at 13000 rpm for 15 minutes 
at 4°C. After the supernatant was removed, the pellet was air dried for 5 minutes at 
room temperature and dissolved in sterile deionized water. Then 1 µl of RnaseOut 
(40U/µl, Invitrogen, USA) was added into total RNA solution to remove RNase and 
stored at ­70°C. 
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 3.3.2.2 Synthesis of cDNA 
 The RNA was converted to first strand cDNA using reverse 
transcriptase enzyme with oligo­dT18 and random hexamer primers. The first strand 
synthesis will be started at the 3’ end of poly (A)+ mRNA by using the oligo­dT 
primer. The total volume of the reaction was 100 µl which consisted of 10 µg RNA, 2 
µM oligo­dT primer, 8 ng of random hexamer primers, and 0.125 mM of dNTPs 
(Promega, USA), 200 units of MMuLV reverse transcriptase  (200U/µl, NEB, USA) 
and 160 units of RNaseOut (40U/µl, Invitrogen, USA), all were dissolved in 1 × RT 
buffer. The RNA was heated to at 90C for 5 minutes and quickly chilled on ice 
before it was added to the reaction. The reaction was incubated at 42C for 2 hours 
and then the reaction was heated to 95C for 3 minutes and quickly chilled on ice. 
After that, the PCR reaction was performed as described below. The second strand 
synthesis was done using the mRNA/DNA as a template. The cDNA was kept at ­
20°C. 
 
 3.3.2.3 Amplifying and reassembling heavy and light chain sequences 
 The genes for variable regions of heavy chain, κ light chain, and λ 
light chain (VH, Vκ, and Vλ) were amplified separately and recombined by three 
subsequent PCR reactions. The first set of PCR consists of 79 independent reactions 
to generate variable domains of the heavy and light chains. The heavy chain 5' 
primers were designed to include a SfiI site, and the light chain 3' primers include a 
NotI site (Table 5). Light chain 5' primers were designed to include part of the linker 
region (Gly4Ser)3 and compatible with the heavy chain 3' primers. The total volume 
of each reaction was 50 µl which consisted of 2.5­5 µl of reaction from previous step, 
1 µM of each forward and reverses primers, 200 µM of dNTPs, 1× ThermoPol buffer, 
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2.5 units of Taq DNA polymerase enzyme (5U/µl, NEB, USA), 1.25 units of Pfu 
DNA polymerase enzyme (3U/µl, Promega, USA) and 0.1 mg/ml of BSA. The PCR 
cycles were initiated by pre­denaturing at 94°C for 5 minutes, following by 35 cycles 
of denaturation at 94°C for 1 minute, annealing at 57­65°C for 1 minute, extension at 
72°C for 2 minutes. The final extension was performed, by heating the reaction to 
72°C for 10 minutes. The heavy chain primers were modified to include a SfiI site and 
linker sequence whereas the light chain primers were generated a NotI site and a 
linker sequence. Equal amount of PCR products were pooled into collections of VH, 
Vκ, and Vλ gene repertoire, and purified from the low melting temperature agarose 
gel according to standard protocol. 
 In the second PCR, heavy and light chains were assembled and 
amplified using Pfu DNA Polymerase (Promaga, USA). The assembly PCR reaction 
contained equal molar mixture of the pooled heavy (VH) DNA and pooled light (Vκ, 
or Vλ) gene repertoire. The total volume of the PCR reaction was 50 µl, which 
consisted of equal molar amounts of DNA, approximately 500­1,000 ng, 200 µM of 
dNTPs, and 1.25 units of Pfu DNA polymerase enzyme (3U/µl, Promega, USA), all 
in 1× pfu DNA polymerase buffer. The separated heavy and light chain fragments 
were converted to scFv by amplification under the following conditions: five cycles of 
denaturation at 94°C for 45 seconds, annealing at 60°C for 50 seconds and extension 
at 72°C for 1 minute. The correctly linked products from the assembly step were 
extended by PCR under the following conditions: 30 cycles of denaturation at 94°C 
for 1 minute, annealing at 60°C for 1 minute and extension at 72°C for 2 minutes. 
This was followed by the final extension at 72°C for 10 minutes. 
 The third reaction created a full­length scFv gene repertoire from 
the second PCR by PCR amplification in the presence of pull­through primers. This 
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PCR extended the scFv gene from the SfiI and NotI sites flanking scFv genes, using 
the following primers: PTfw (5'­CCT TTC TAT GCG GCC CAG CCG GCC ATG 
GCC­3') and PTrv (5'­CAG TCA TTC TCG ACT TGC GGC CGC ACG­3'). The 
reaction was performed using the Taq polymerase and 1 μl of assembled products 
from the second PCR. This pull­through PCR was cycled 30 times (94°C for 1 min, 
60°C for 1 min, 72°C for 2 min), and a final extension at 72°C for 10 min. Then the 
samples were purified by a QIAquick PCR Purification Kit (QIAGEN, Germany) for 
the next step. 
 
 3.3.2.4 Cloning of scFv fragments into pMOD1 vector 
 The scFv fragments DNA were inserted into pMOD1 vector 
(Pansri et al. 2009) between SfiI and NotI sites. The DNA of scFv fragments and 
pMOD1 vector was sequential digested with SfiI (20U/µl, NEB, USA) and NotI 
(10U/µl, NEB, USA) enzymes, respectively, to generate compatible sticky ends. The 
digestion reactions of scFv fragments and pMOD1 vector were performed separately, 
each in a total volume of 500 µl. For the SfiI digestions, the reaction mixtures 
consisted of 10 µg of insert DNA, 12 µg of vector DNA, 1x NEB buffer 2, 1 µg/ml 
BSA and 200U of SfiI (20U/µl, NEB, USA). The reactions were incubated at 50°C for 
16 hours. The SfiI digested DNA was cleaned by Wizard clean up kit (Promega, USA) 
before the next digestion step. The NotI digestion mixtures consisted of 400 µl of 
purified SfiI digested DNA, 1× NEB buffer 3, 1 µg/ml BSA and 100 U of NotI 
(10U/µl, NEB, USA). The reaction mixtures were incubated at 37°C for 16 hours. 
After the digestion, the SfiI/NotI digested vector was dephosphorylated by adding 3 µl 
of CIP enzyme (10U/µl, NEB, USA) and incubated at 37ºC for 1 hour. After the 
dephosphorylation, the vector was inactivated by heat at 65ºC for 15 minutes. The 
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inserts and vectors were separated from stuffer fragments by gel electrophoresis 
followed by Wizard clean up kit (Promega, USA). The scFv DNA was ligated into 
pMOD1 vectors at a 3:1 ratio. The total volume of ligation reaction was 200 µl, which 
consisted of 2.8 µg of inserted DNA, 5.5 µg of pMOD1 vector, 1× T4 DNA ligase 
buffer and 15 µl of T4 DNA ligase (400U/µl, NEB, USA). After 16 hours of 
incubation at 16ºC, the ligation reaction was concentrated to 40 µl by precipitating 
overnight with 3 M sodium acetate pH 5.2 plus absolute ethanol. The ligation reaction 
was then transformed into 600 µl of E.coli TG1 cells by electroporation method. The 
reaction was done in two separate cuvettes by pipetting 20 µl of ligated sample into a 
2 mm cuvette containing 300 µl of E.coli TG11 competent cells. The electroporation 
was performed at 2.5 kV, 25 µF, 200 Ω and τ approximately 4 msec using an 
electroporation machine (Eppendrof 2510, Eppendrof, USA). The cuvette was flushed 
immediately with 3 ml of SOC medium (20g Bacto Tryptone, 5g Bacto Yeast Extract, 
2ml of 5M NaCl, 2.5ml of 1M KCl, 10ml of 1M MgCl2, 10ml of 1M MgSO4, 20ml of 
1M glucose, 1L distilled H2O)  at room temperature, and the two separate 
transformation reactions were combined in 50 ml polypropylene tube. The 6 ml of 
combined transformed cells were incubated at 37ºC for 1 hour. After that the 
transformed cells were spread on eight 24×24 cm plates, containing TYE medium (10 
g tryptone, 5 g yeast extract, 8 g NaCl and 15 g bacto­agar in 1 L distilled H2O), 100 
µg/ml ampicillin plus 1% glucose, and incubated overnight at 37ºC. 
 The size of the library was quantified by spreading dilutions of the 
transformation reaction on separate plates. A volume of 100 µl from transformation 
reactions was taken and a four­step 10­fold serial dilution was made. Then 100 µl of 
non­diluted and the four dilutions were spread on separate TYE agar plates containing 
100 µg/ ml ampicillin and 1% glucose. The vector ligation control was performed in 
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parallel to evaluate the background of library. Ligation efficiency was also determined 
by counting the number of colonies from no­insert ligation. 
 The large plates of library were scraped into 20 ml of 2×YT 
medium (16 g tryptone, 10 g yeast extract and 5 g NaCl in 1 L distilled H2O) with 
20% glycerol and aliquoted into freezing vials. The glycerol stock of library was 
stored at ­70ºC.  The library size was determined by serial plating on TYE plates 
containing 100 µg/ ml ampicillin and 1% glucose and incubated overnight at 37°C. 
 
 
Figure 3.2 Schematic outline of the strategy used for the construction of 
recombinant scFv antibody library from immunized rabbit (Pansri et al. 
2009). 
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Table 3.3 Listing of primers for PCR amplification of rabbit antibody heavy and 
light chain variable regions. 
 
Primer 
 
Numbers 
 
Sequence 
VH5’SfiI 1 
 
5’CCT TTC TAT GCG GCC CAG CCG GCC ATG GCC CAG TCG 
GTG GAG GAG TCC RGG 3’ 
 
2 5’CCT TTC TAT GCG GCC CAG CCG GCC ATG GCC CAG TCG GTG AAG GAG TCC AGA 3’ 
3 5’CCT TTC TAT GCG GCC CAG CCG GCC ATG GCC CAG TCG YTG GAG GAG TCC GGG 3’ 
4 5’CCT TTC TAT GCG GCC CAG CCG GCC ATG GCC CAG SAG CAG CTG RTG GAG TCC GG 3’ 
5 5’CCT TTC TAT GCG GCC CAG CCG GCC ATG GCC CAG TCG CTG GAG GAG TCC GGG GGT 3’ 
VH3’linker 
1 
5’GCC AGA ACC GCC TCC CCC CAT CCC TCC GCC ACC CGA 
TGG GCC CTT GGT GGA GGC TGA RGA GAY GGT GAC CAG 
GGT GCC 3’ 
 
2 5’ GCC AGA ACC GCC TCC CCC ACT CCC TCC GCC ACC GAC TGA YGG AGC CTT AGG TTG C 3’ 
VLκ5’linker 1 5’ AGT GGG GGA GGC TCT GGC GGA GGT GGG TCG GAG CTC GTG MTG ACC CAG ACT CCA 3’ 
 
2 5’ AGT GGG GGA GGC TCT GGC GGA GGT GGG TCG GAG CTC GAT MTG ACC CAG ACT CCA 3’ 
3 5’ AGT GGG GGA GGC TCT GGC GGA GGT GGG TCG GAG CTC GTG ATG ACC CAG ACT GAA 3’ 
4 5’ AGT GGG GGA GGC TCT GGC GGA GGT GGG TCG GCT CAA GTG CTG ACC CAG AC 3’ 
5 5’ AGT GGG GGA GGC TCT GGC GGA GGT GGG TCG GMC MYY GWK MTG ACC CAG ACT CC 3’ 
VLλ5’linker 1 5’ AGT GGG GGA GGC GGT TCT GGC GGA GGT GGG TCG GAG CTC GTG CTG ACT CAG TCG CCC TC 3’ 
 2 5’ AGT GGG GGA GGC GGT TCT GGC GGA GGT GGG TCG CAG CCT GTG CTG ACT CAG TCG  3’ 
VLκ5’NotI 1 5’ CAG TCA TTC TCG ACT TGC GGC CGC ACG TTT GAT TTC CAC ATT GGT GCC 3’ 
 
2 5’ CAG TCA TTC TCG ACT TGC GGC CGC ACG TAG GAT CTC CAG CTC GGT GCC 3’ 
3 5’ CAG TCA TTC TCG ACT TGC GGC CGC ACG  TTT GAC SAC CAC CTC GGT GCC3’ 
VLλ5’NotI 1 5’ CAG TCA TTC TCG ACT TGC GGC CGC GCC TGT GAC GGT CAG CTG GGT CCC 3’ 
 2 5’ CAG TCA TTC TCG ACT TGC GGC CGC ACC TGT GAC GGTCAG CTG GGT CC 3’ 
 
Note: S=G/C; R=G/A; K=G/T; M=A/C; Y=C/T; W=A/T; H=A/C/T; B=C/G/T; V=A/C/G; 
D=A/G/T; N=A/T/G/C. Bold fonts indicate linker sequence. Recognition sites for restriction 
enzymes (SfiI/NotI), and linker sequence are italicized. 
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 The quality of library was determined by restriction fragment 
analysis. The colonies were randomly picked into 5 ml media containing appropriate 
antibiotic. After the cultures were incubated for 16­18 hours at 37oC with shaking, the 
cultures were centrifuged at 6800xg for 3 minutes to collect the cells for DNA 
extraction. Then plasmid minipreparations were made from each clone (QIAgen spin 
Mini­prepkit, USA). Digestion reactions of DNA were performed in a total volume of 
10 µl. The reaction mixtures consisted of 2 µl of DNA, 0.2 µg of vector DNA 1× 
NEB buffer 3, 1 µg/ml BSA, 1 U of NcoI and 1 U of NotI. The reaction was incubated 
at 37°C overnight and was run on 1 % (w/v) agarose gel (Emresco, USA) in TAE 
buffer at 100 volts for 45 minutes.  The diversity of library was performed by 
restriction fragment analysis using BstNI enzyme. The digestion reactions of DNA 
were performed in a total volume of 10 µl. The reaction mixtures consisted of 2 µl of 
DNA, 0.2 µg of vector DNA 1×NEB buffer 3, 1 µg/ml BSA, 1 U of BstNI. The 
reactions were incubated at 65°C for overnight and were run on 1 % (w/v) agarose gel 
in TAE buffer at 100 volts for 45 minutes. 
 
 3.3.3 Amplification of phage library for bio-panning 
 To rescue phagemid library,  the 500 µl library stock was add into 50 ml 
pre­warmed 2×YT containing 100 µg/ml ampicillin (Emresco, USA)  and 1% (w/v) 
glucose (Carlo erba, Italy) and grow with shaking at 37oC until the cell reached to the 
mid­log phase (OD600 about 0.4). The 2×10
11 KM13 helper phage was added into 50 
ml cultures and was then incubated at 37oC without shaking for 30 minutes. The 
culture was centrifuged at 4,000 rpm for 10 minutes following by resuspension of the 
cell pellet in 100 ml of 2×YT containing 100 µl/ml ampicillin, 50 µg/ml kanamycin 
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(Fluka, Switzerland) and 0.1 % glucose. After that the culture was incubated with 
shaking at 30oC overnight. The next day, the overnight culture was centrifuged at 
4,000 rpm for 30 minutes. The supernatant was precipitated by using PEG (Fluka, 
Switzerland) /NaCl (Emresco, USA) (20 % Polyethylele glycol 6000, 2.5 M NaCl) for 
1 h on ice followed by centrifugation at 4,000 rpm for 30 minutes. All supernatant 
was removed; the pellet was resuspended in phosphate buffered saline (PBS, 137 mM 
NaCl, 3 mM KCl (Emresco, USA), 8 mM Na2HPO4 (Merck, Germany), 1.5 mM 
KH2PO4 (AnalaR, England), pH 7.4). The phage solution was centrifuged at 10,000 
rpm for 10 min. To remove any pellet, the phage library solution was transferred to 
new tube and stored at 4oC before biopanning. For long term storage, phage 
supernatant was kept in 20% glycerol (Emresco, USA)/PBS and stored at ­70oC. To 
determine the phage titer, the PEG precipitate phage was diluted by making six 100­
fold serial dilutions and adding 100 µl of diluted phage into 900 µl of mid­log E. coli 
TG1. The infected E. coli TG1 cells were incubated at 37oC for 30 minutes followed 
by plating on separate 2×YT agar containing 100 µg/ml ampicillin and 1% (w/v) 
glucose. The plates were incubated at 37oC overnight. 
 
 3.3.4 Biopanning against Bradyrhizobium sp. DOA9 
 The phage antibody library was used for selecting the phage particles that 
specifically bind to immobilized antigen. The biopanning method was done to select 
phage clone that specific binding with strain DOA9 from naïve human library and 
immunized rabbit library from the step 3.3.2 according to the protocol described by 
Pansri et al. (2009). 
 Broth culture antigen preparation for biopanning: The DOA9 strain was 
grown in 50 ml flask containing yeast extract mannitol broth (YMB) at 28°C, 200 rpm 
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for 5 days. Cell pellets were harvested aseptically in sterile saline buffer (0.85% 
NaCl), then washed three times in sterile saline by centrifugation at 4500 rpm, 20 min 
at 4°C. Cell pellets were re­suspended in saline buffer and were adjusted to 1×109 
cells/ml. This could be estimated by reading the optical density of the suspension on a 
spectrophotometer.  An optical density of 0.45 (OD600) is approximately equal to 1 × 
109 cells/ml. Then, the suspension was treated by boiling in water bath for 1 h to 
inactivate flagella and other protein antigens. The total protein was determined by 
Bradford assay (Bradford 1976) The merthiolate as a preservation was added to 
achieve a final concentration of 1:10,000. The stock solution was stored at ­20°C until 
use. 
 The selection was done on immunotube (Nunc, Denmark) with 
immobilized antigen. The 20 µg antigen was immobilized in 400 µl of 100 mM 
NaHCO3 pH 8.5. The immobilizing was performed overnight at 4ºC.  Next day, the 
tube was washed three times with PBS. The immunotube was then blocked to avoid 
non­specific binding of phage particles with 2% (w/v) skimmed milk (2% MPBS) and 
incubated at room temperature for 2 hours with rotating. The blocking solution was 
poured off and the well was washed three times with PBS. Then 300 µl of 2% MPBS 
and containing 1012 phages from the phage antibody library was added to the tube and 
incubated at room temperature for 1 h with rotating and 1 h on bench at room 
temperature. The unbound phages were removed by washing three times with PBS 
containing 0.1% (v/v) tween 20 (PBST) and two times with PBS. After shaking out 
the wash buffer and repeating this washing step for ten times, the well was rinsed with 
PBS ten times. The bound phages could be eluted by trypsinization or/and low pH 
condition using acidic elution buffer (50 mM glycine­HCl pH, 2.0). The trypsinization 
was performed by adding 50 µl of freshly prepared trypsin buffer (5 µl of 10mg/ml 
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trypsin stock in 45 µl of PBS) to the well and leaving it for 10 minutes at room 
temperature. The low pH elution was performed by using 50 µl of 50 mM glycine­
HCl pH, 2.0, to be elution buffer. After incubation at room temperature for 10 
minutes, the acidic solution had to be neutralized by adding 50 µl of neutralization 
solution (200 mM NaHPO4 pH 7.5). The recovered phages were amplified in E.coli 
TG1 cells by infecting 175 µl of mid­log phase E.coli TG1 at OD600 of 0.4 with 25 µl 
of eluted phages and incubating at 37ºC for 30 minutes. For the output titering, the 
eluted phages were diluted. Three 10­fold serial dilutions were performed. Then 100 
µl of non­diluted and the three dilutions were separately spread on TYE agar plates 
containing 100 µg/ ml ampicillin and 1% (w/v) glucose. The plates were incubated at 
37ºC overnight. 
 To continue with the next round of selection, 1 ml of 2 × YT media was 
added on agar plates containing a lawn of infected bacteria, and the cells were 
loosened with a glass spreader. The scraped cells were kept as a 15% (v/v) glycerol 
stock at ­70°C, and 10 μl of scraped bacteria were added into 10 ml of 2 × YT 
supplemented with 100 μg/ml ampicillin and 1% (w/v) glucose, and incubated at 
37°C with shaking until the OD600 was 0.4 (approximately 2 h). After this procedure, 
phage was rescued by super­infecting the cells with 5 × 1010 helper phage KM13 and 
incubated at 37 °C, without shaking, for 30 minutes. Afterward, the culture media was 
exchanged by centrifugation at 4,000 rpm at 4°C for 15 minutes, the supernatant was 
removed, and the pelleted bacteria were resuspended in 5 ml of 2 × YT containing 
100μg/ml ampicillin, 50 μg/ml kanamycin, and 0.1% (w/v) glucose. Later, it was 
incubated at 30°C with shaking overnight. On the following day, the overnight culture 
was centrifuged at 4,000 rpm and 4°C for 15 minutes. Phage was precipitated by 
adding 1 ml of PEG/NaCl (20% (v/v) polyethylene glycol 6000 in 2.5 M NaCl) into 4 
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ml of the supernatant and kept on ice for 1 h, and later centrifuged at 4,000 rpm, at 
4°C for 30 minutes. The supernatant was removed and the pellet was resuspended in 
100 μl PBS for the next round of selection. 
 
 3.3.5 Individual Phage Rescue 
 Individual phage­infected colonies were randomly picked from the TYE 
plate and grown in wells of a 96­well plate (Nunc, Denmark) containing 100 μl 2 × 
YT plus 100 μg/ml ampicillin and 1% (w/v) glucose. After overnight incubation at 37 
°C, small inocula (5 μl) from each well were transferred to a second 96­well plate 
containing 200 μl of 2 × YT plus 100 μg/ml ampicillin and 1% (w/v) glucose. The 
first plate was kept as master stock by adding glycerol to a final concentration of 20% 
(v/v) and kept at ­20 °C. The second plate was incubated with shaking at 37 °C for 2 
h, and later phage was rescued by adding 1010 helper phage to each well. Following 
this they were then incubated at 37 °C for 1 h before centrifugation of the plate at 
4,000 rpm for 10 minutes. The supernatant was discarded and the pellet was 
resuspended in 200 μl of 2 × YT containing 100 μg/ml ampicillin and 50 μg/ml 
kanamycin, and cultured at 30°C overnight (20 h) with shaking (250 rpm). The 
overnight culture was spun at 4,000 rpm for 10 minutes, and 50 μl of the supernatant­
containing phage was used in monoclonal phage ELISA. 
 
 3.3.6 Screening for specific binder by monoclonal phage ELISA 
 Broth culture antigen was prepared with the same method for biopanning. 
Then, the broth culture antigen was dilute in sodium carbonate buffer and calculated 
with 5µg protein total per wells of 96 MicroWell™ plates (Nunc, Denmark). For 
negative control, wells were coated with 2% (w/v) skim milk in sodium carbonate 
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buffer. After incubation at 4 °C overnight, the plates were washed three times with 
PBS. The wells were then blocked with 4% (w/v) MPBS for 2 h at room temperature. 
The wells were re­washed three times with PBS. Then, one hundreds μl of phage 
supernatant and 50 μl of 4% (w/v) MPBS were added to each well and incubated at 
room temperature for 2 h. Unbound phage was removed by washing three times with 
PBST and three times with PBS. Subsequently, 100 μl of HRP­labeled anti­M13 
(1:5000 dilution in 2% (w/v) MPBS) was added into each well. After incubation for 
an additional 1 h at room temperature, the wells were washed again, as described 
previously, and 100μl of ABTS substrate solutions were added into each well and 
incubated at 37°C for 30 min. The resulting absorbance was read at 405 nm by plate 
ELISA reader (Sunrise, TECAN, Austria). 
 
3.4 Detection of DOA9 strain by phage ELISA 
 3.4.1 In pure culture sample 
 To determine the optimum value of antigen for phage ELSIA, the antigen 
was prepared as described above. Then, the broth culture antigen was diluted in 
sodium carbonate buffer and calculated with variable amount of total protein (4, 5, 6, 
and 7 µg) per wells of 96 MicroWell™ plates (Nunc, Denmark). The procedure 
ELISA was done according to the protocol described by Pansri, Jaruseranee et al. 
(2009). The broth culture antigen was dilute in sodium carbonate buffer and 
calculated with 5 µg protein total per wells. The wells were sealed with tape to avoid 
evaporation and incubated overnight at 4°C. Next day, the wells were rinsed three 
times with PBS and blocked with 2% skim milk in phosphate buffer saline (MPBS) 
for 2 hours, at room temperature with rotating. Then the wells were rinsed three times 
with phosphate buffer saline (PBS). After that, phage stock (about 1012pfu) was added 
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to wells containing 50 µl of 4% MPBS. Then, wells were washed three times with 
PBST (PBS with 0.1% Tween 20) followed by three times of PBS. Secondary 
antibody was used for detecting the bound phages. The 1:5000 dilution of a mouse 
anti­M13 phage­horseradish peroxidase (HRP) conjugate (Amersham­Pharmacia 
Biotech, Sweden) in 50 µl of 2% MPBS was added into each well as secondary 
antibodies. The plates were incubated at room temperature for 1 h with rotating. The 
wells were washed as described above. The 100 µl of ABTS (2, 2­azino­di­3­ethyl­
benzthiazoine­6­sulfonate) peroxidase substrate (Fluka, USA) containing 0.05% H2O2 
was added, and the plates were incubated at room temperature for 1 h. The assay was 
performed in triplicate. The reaction was stopped by adding 50 µl of 1% sodium 
dodecyl sulfate. Detection was done by measuring the absorbance at OD 405 nm in an 
ELISA plate reader (Sunrise, TECAN, Austria). 
 To test cross reactivity of positive phage clones and polyclonal antibody, 
the phage ELISA was done the same with above phage ELISA with optimum value of 
antigen. For negative control, other bacterial strains (SUTN9­2, SUTN1­12, 
USDA110, SUT 47, SUT 19, TAL173 and PRC 008) and Bacillus sp. were used in 
phage ELISA. Besides, 3C1 phage clone (against aflatoxin) was used as negative 
phage control in the test. For polyclonal antibody, the antibody prepared from rabbit 
immunized with DOA9 was diluted 1:7500 in PBS buffer and add 100 µl/well 
containing 50 µl of 4% MPBS. The binding was done at room temperature for 1 h 
with rotating. Secondary antibody was used for detecting the bound phages and 
polyclonal antibody. A 1:5000 dilution in PBS of protein A was added for polyclonal 
antibody wells as secondary antibodies. The next steps was the same as above 
procedure. 
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 3.4.2 In nodule sample 
 Nodule antigen preparation: The seeds of siratro (Macroptilium 
atropurpureum) were sterilized by soaking in concentrated sulfuric acid for 10 
minutes. After that, all seeds were washed with sterilized water five times and then 
soaked in sterilized water overnight at room temperature under dark condition. All 
seeds were germinated on sterilized 0.8% (w/v) water agar for 2 days in the dark 
conditions at room temperature. The germinated seeds were planted in Leonard’s jars 
and inoculated with 1 ml of 1×109 cells/ml of each Bradyrhizobium strain, DOA9, 
SUTN 9­2, SUTN 1­12, and USDA110. All plants were supplemented with N­free 
medium (Hoagland et al. 1950) and grown in a room for 1 month. After 4 weeks, 
nodules were collected from plants. Then, nodules were washed with sterile distilled 
water and stored over silica gel at room temperature. Prior to analyses, nodules were 
revived by distilled water for 1­2 hours (Payakapong et al. 2003). 
 ELISA was done according to the protocol described by Pansri et al. 
(2009) with some small modifications for nodule samples. Nodules were crushed and 
gently grinded in small mortar. Nodules were calculated with 4 nodules/wells. Then, 
sodium carbonate buffer (pH 8.5) was added to mortar. Finally, 200 µl of the nodule 
suspension was added to the wells of ELISA plate (Nunc, Denmark). The broth 
culture antigen was diluted in sodium carbonate buffer and calculated with 5 µg 
protein total per wells as positive control. The wells were sealed with tape to avoid 
evaporation and incubated overnight at 4°C. Then, the procedure was the same phage 
ELISA for pure culture sample. 
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3.5 Detection of DOA9 by immunofluorescence assay 
Immunofluorescence assay was performed according to the protocol described 
by Somasegaran and Hoben (1994) with some modifications for scFv antibody 
against target in both sample pure culture and nodule. Negative control was made 
using only diluents, no phage, no polyclonal antibody and non­related phage clone. 
The phage clone 3C1 also was used the same phage ELISA for control. 
For pure culture sample, the culture spots on the slide were incubated with 10 
µl of polyclonal antibody (1:7500), phage clone (1012pfu) in one hour. The slide was 
rinsed two times with PBS and incubated with 10 µl of secondary FITC labelled anti­
rabbit Ig antibody (for polyclonal antibody) M13­FITC (for phage clone antibody). 
Then, slides were incubated in the moist chamber for one hour at room temperature. 
Unbound proteins were removed by rinsing and washing with PBS and mounted in 
40% glycerol under a cover slip. The slip was examined under a fluorescence 
microscope (Nikon, Japan). 
For nodule sample, the section (30µl) of nodule was placed on slides. Then, 
sections were incubated in PBS containing calcofluor white M2R (Sigma, Germany) 
to a final concentration of 0.01% (w/v) for staining of the plant cell wall. After 
washing with PBS, the procedure was done the same for pure culture samples. 
Finally, the slip was examined under a fluorescence microscope (Nikon, Japan). 
 
3.6 Sequence analysis and structure modeling 
Plasmid DNA from positive scFv phage clones were extracted and purified 
from overnight culture by using a commercially plasmid preparation kit (Mini Preps: 
Qiagen, Germany) and were  completely sequenced by Macrogen (Seoul, Korea) 
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using primers: For VH use link seq new CGA CCC GCC ACC GCC GCT G and For 
V use pHEN seq CTA TGC GGC CCC ATT CA. Sequences of scFvs were aligned 
and analyzed with rabbit germline sequence via http://www.imgt.org (IMGT®, the 
international ImMunoGeneTics information system®). For 3D structure modeling, the 
nucleotide sequence was translated to an amino acid sequence using the Translate 
Program (Expert Protein Analysis System, Expasy). 
Docking between recombinant scFv antibodies and antigen was performed to 
determine possible binding regions by in silico prediction tools of the three 
dimensional structure (Kelley 2009) and used the PDB file on PyMol (The PyMOL 
Molecular Graphics System, Version 1.7.4 Schrödinger, LLC). 
 
3.7 Production of soluble scFv antibodies 
 3.7.1 Subcloning and expression in E. coli HSM174 
 The genes of positive scFv antibody clones, RD6/2 and RB8 were 
subcloned into pET27b vectors between NcoI and NotI sites. Plasmids were purified 
from each clone (QIAgen spin Mini­prepkit, USA) and transformed into E. coli HSM 
174. The E. coli harboring recombinant plasmid was grown at 37oC in 5 ml of M9ZB 
media (1% Tryptone, 0.5% Sodium Chloride, 1XM9 Salts, 0.4% Glucose, 1mM 
Magnesium Sulfate) containing 50 µg/ml kanamycin and 2% w/v glucose. The culture 
was incubated overnight with shaking at 30oC. One percent (v/v) of each overnight 
culture was used to inoculate into M9ZB media supplemented with 2% (w/v) glucose 
and 50 µg/ml kanamycin. Then, the culture was incubated with shaking at 30oC for 4 
hours. After that, the cells were centrifuged at 16oC, 5000 rpm for 15 min followed by 
resuspension with M9ZB media containing 1% (w/v) glycerol, 50 µg/ml kanamycin 
and 1 mM isopropylthio­galactoside (IPTG, Emresco, USA). After continuing 
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incubation at 16oC for 20 hours with shaking, the cell pellet was collected by 
centrifugation at 16oC, 8000 rpm for 15 min for 15 min. The secreted antibody could 
be found in the supernatant. The hexahistidine tag was used for detection and 
purification. 
 
 3.7.2 Purification of soluble scFv antibody 
 The recombinant scFv antibodies containing a hexahistidine tag was 
purified using Ni++ ions immobilized on resin by covalent linkage to nitrilotriacetic 
acid (NTA). The supernatant was immediately applied to a Ni–NTA agarose affinity 
column containing 1­2 ml of bed volume (QIAGEN GmbH, Hilden, Germany), and 
the chromatography was carried out gravitationally at 4oC, following the Qiagen’s 
protocol. The column was washed two times with 50 ml of wash buffer (20 mM Tris–
HCl buffer, pH 8.0 and 150 mM NaCl) containing 20 mM imidazole. Ni–NTA bound 
enzyme was eluted with 250 mM imidazole in the same buffer. The eluted fractions 
were then dialyzed by snake skin dialysis bag followed by centrifugal dialysis using 
Amicon® Ultra­4 Centrifugal Filter Devices (Mr 10,000 cut­off, Millipore, Ireland) to 
remove imidazole and concentrated soluble scFv antibody. SDS­PAGE 
electrophoresis was used to monitor antibody purity. 
 
 3.7.3 Soluble scFv antibody ELISA 
 The Immuno 96 microWellTM plate (Nunc, Denmark) was immobilized 
with pure culture and nodule sample. The procedure is the similar with phage ELISA 
with some small modifications for soluble scFv antibodies. The soluble scFv 
antibodies were detected with His prob­HRP (1:5000). The color of the reaction was 
developed with ABTS reagent (Fluka, Switzerland).  The reaction was quantified by 
measuring the absorbance at OD 405 nm. 
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CHAPTER IV 
RESULTS AND DISCUSSIONS 
 
4.1 Phage display library construction from immunized rabbit 
 4.1.1 RNA extraction and cDNA synthesis 
The total RNA was prepared from rabbit spleen samples by TRIzol reagent 
(Invitrogen, USA) according to the manufacturer’s protocol. The RNA extracts were 
high purity, free of DNA contamination and allowed production of first strand cDNA 
by using MMuLV reverse transcriptase (NEB, USA) and a mix of oligo­dT18 and 
random hexamers primers (Figure 4.1). 
 
 
 
Figure 4.1 The total RNA on 1% agarose gel and stained with 0.5 µg/ml of 
ethidium bromide. Lane 1: 1 kb DNA marker; Lane 2: sample. 
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 4.1.2 Amplifying and reassembling heavy and light chain sequences 
In order to reduce amplification biases, 26 independent PCRs were 
performed using all possible combinations within a designed primer set (Table 4) that 
encompasses the entire theoretical set of whole repertoires of rabbit antibody genes. 
The PCR reactions included five VH forward primers (VH5'SfiI) paired with two VH 
reverse primers (VH3'link) which generated a total of ten reactions; whereas three Vκ 
forward primers (VL5'link­κ) paired with two Vκ reverse primers (VL3'NotI­κ) 
generated a total of six reactions; and five Vλ forward primers (VL5'link­λ) paired 
with two Vλ reverse primers (VL3'NotI­λ) generated a total of ten reactions. The 
PCRs led to the representation in the repertoire of variable regions derived from all 
conceivable framework assemblies. 
The scFv fragments were constructed by assembly of VH and VL genes 
together with linker, which generated VH­linker­VL orientation. In order to create 
scFv fragment genes of a VH­linker­VL type, the separate VH and VL genes were 
converted to a scFv gene by inserting a linker DNA sequence. The assembly of VH, 
VL, and linker fragment was carried out by PCR. The 3′ ends of VH gene 
complementary to 5′ ends of linker sequence and the 3′ ends of this linker DNA was 
complementary to 5′ ends of VL gene. The final pull­through PCR was done with two 
primers (PTfw & PTrv) compatible to the 5' SfiI or 3'NotI segments of the heavy and 
light chain gene repertoires. The size of scfv fragment was approximately 800 bp 
(Figure 4.2). 
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Figure 4.2 PCR products of VH and VL genes and scFv fragment on 1% agarose 
gel and stained with 0.5 µg/ml of ethidium bromide.  M: Marker 100bp. 
 
 4.1.3 Cloning of scFv fragments into pMOD1 vectors 
 The fragments were digested with NotI/SfiI and ligated into NotI/SfiI­
linearized pMOD vector. The recombinant vector was introduced into competent E. 
coli TG1 cells and the transformants were pooled. Finally, the library was obtained 
with 3.5×106 independent clones. The investigation of full­length inserts from some 
randomly clones using NcoI and NotI restriction enzyme digestion showed that 85% 
of all clones had inserted fragment (Figure 4.3). 
 
 4.1.4 Diversity analysis of antibody fragments 
 To analyze the diversity of the scFv repertoire and the quality of the 
primary library, DNA segments encoding the scFv genes from each positive clone 
above were examined by BstNI digestion, and their fingerprint patterns were 
compared. The result showed that clones have different patterns (Figure 4.4). 
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Figure 4.3 DNA fragment of random clones from unselected library after digestion 
with NcoI and NotI restriction enzyme on 1% agarose gel and stained 
with 0.5 µg/ml of ethidium bromide. M: Marker 1kb; 1­20 randomly 
clones. 
 
 
Figure 4.4 DNA fragment of random clones from unselected library after digestion 
with BstNI restriction enzyme on 1% agarose gel and stained with 0.5 
µg/ml of ethidium bromide. M: Marker 100 bp; 1­16 phage clones. 
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4.2 Selection of scFv fragments specific to DOA9 by biopanning 
In order to select the best recombinant scFv phage antibody against target, two 
scFv antibody libraries, naïve human library (Yamo library) and immunized rabbit 
library constructed in this study were used in biopanning with target antigen, DOA9 
in immunotube. Three rounds of selection and amplification of the bound phages were 
performed. As show in Table 4.1, a significant enrichment of specific scFv phage 
antibody was observed during the three time panning. 
 
Table 4.1 Selective enrichment of scFv antibodies during biopanning process with 
rabbit library. 
 
Rounds 
 
Amount of 
antigen (µg) 
 
Input 
(CFU) 
 
Ouoput 
(CFU) 
 
Output rate 
% 
 
1st 
 
20 
 
1.0 x 1012 
 
2.57 x 104 
 
2.57 x 10­6 
2nd 15 1.0 x 1012 1.72 x 105 1.72 x 10­5 
3rd 10 1.0 x 1012 1.02 x 106 1.02 x 10­4 
 
Output rate (%) = (numbers of phage output × 100) / (numbers of phage input) 
 
After each round of panning, 192 clones (two 96­well plates) were picked 
randomly and tested for affinity to target by phage ELISA. Finally, in third round of 
panning, two positive phage clones, RB8 and RG9 were selected from immunized 
rabbit library with high affinity with DOA9 target (Figure 4.5).  Two clones, RB8 and 
RG 9 were used for the further studies. 
Similarly, for naïve human library, only one round was performed against 
target DOA9. The result showed in Figure 4.6, one phage clone RD6/2 had high 
signal ELISA with DOA9 target. This clone was used for the further studies. 
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Figure 4.5 Binding of specific phage to DOA9 target from third round of panning 
with immunized rabbit scFv antibody library. 
 
 
 
Figure 4.6 Binding of specific phage to DOA9 target from first round of panning 
with naïve human scFv antibody library. 
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4.3 Detection of DOA9 strain by phage ELISA  
In order to evaluate the potential application of recombinant scfv antibody for 
detecting and monitoring DOA9 in production of bio­fertilizer, positive phage scfv 
antibody was tested with both bacterial sample in broth and in nodule by two 
methods, phage ELISA and immunofluorescence assay. 
The limitation of antigen amount for detection by phage ELISA is 4 μg of total 
protein, while the optimum amount of antigen for detection was 5 μg (Figure 4.7). 
Then, the all ELISAs in next steps were conducted with 5 μg of protein for pure 
culture sample. 
 
 
Figure 4.7 Phage ELISA of scFv clones against DOA9 in pure culture with variable 
antigen amounts. Value indicated mean of triplicate reactions. Error bars 
showed the standard derivation for each set of data. RB9 and RG8 phage 
clones from rabbit library; RD6/2 phage clone from human library. 
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The binding of three positive clones RB8, RG9, RD6/2 and poly clonal 
antibody were tested by phage ELISA to bind with pure culture and nodule sample 
were shown in Figure 4.8 and 4.9, respectively. The results showed that, phage clones 
had high affinity with the target DOA9 in both pure culture and nodule antigen, while 
polyclonal antibody still had cross reactivity with other bacterial strains. No signal 
was observed with negative control phage, 3C1 (specific phage clone for mycotoxin 
antigen). Interestingly, the phage clones have no cross­reactivity with other antigens 
from related rhizobial strains, USDA110, SUTN 9­2 and SUTN 1­12. These results 
suggest that phage clones are more specific with DOA9 than polyclonal antibody. 
 
 
Figure 4.8 Phage ELISA of scFv clones against DOA9 and other antigens in pure 
culture. Value is mean of triplicate reactions. Error bars showed the 
standard derivation for each set of data. RB9 and RG8 phage clones from 
rabbit library; RD6/2 phage clone from human library; 3C1 is negative 
control phage clone. 
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Figure 4.9 Phage ELISA of scFv clones against DOA9 and other antigens in nodule 
sample. Value indicated mean of triplicate reaction. Error bars showed 
the standard deviation for each set of data. RB9 and RG8 phage clones 
from rabbit library; RD6/2 phage clone from human library; 3C1 is 
negative control phage clone. 
 
The phage clones were also checked with some other strains, SUT 47 
(Bacillus sp.), SUT 19 (Pseudomonas sp.), TAL 173 (Bradyrhizobium sp.) and PRC 
008 (Bradyrhizobium sp.). The result showed that phage clones were more specific 
with target DOA9 and no cross reactivity with other targets, while polyclonal 
antibody tended to have higher cross reactivity with tested strains (Figure 4.10). 
In conclusion, the positive phage clones, RD6/2, RB8 and RG9 were specific 
binding to target DOA9 as well as polyclonal antibody. Phage clones also had low 
cross reactivity with other bacterial strains. 
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Figure 4.10 Phage ELISA for checking cross reactivity of phage clones and 
polyclonal antibody with other strains of commercial bacterial 
biofertilizer. Value indicated mean of triplicate reactions. Error bars 
showed the standard derivation for each set of data. RB9 and RG8 phage 
clones from rabbit library; RD6/2 phage clone from human library. 
 
4.4 Detection of DOA9 strain by Immunofluorescence assay 
The reactivity of phage clones RB8 and RG9 (rabbit clones) and RD6/2 
(human clones) against target DOA9 were also confirmed by immunofluorescence 
assays and compared with reactivity of polyclonal antibody and negative phage 
control (3C1). The results were summarized in Figures 4.11 and 4.12. The results 
were the same with phage ELISA experiment. 
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Figure 4.11 Immunofluorescence microscopy of polyclonal antibody and 
recombinant human scFv phage antibodies with some bradyrhizobial 
antigens in form of pure culture and nodule bacteroid.  RD6/2 clone from 
naïve human library; 3C1 clone from naïve human library against 
aflatoxin (for negative control). For pure culture, scale bar is 10 µm and 
magnification is 80×; for nodule sample scale bar is 100 µm and 
magnification is 10×. 
 
The selected phage clones had specific binding activity with DOA9 target 
antigen in both pure culture and nodule sample. No fluorescence was obtained with 
the negative controls which consisted of no phage, no polyclonal antibody, and 
mycotoxin­specific phage clone (3C1 clone). The blue color was detected as 
calcofluor binding with plant cell.  Polyclonal antibody also still had cross reactivity 
with other Bradyrhizobium strains, such as SUT 9­2, SUT1­12, and USDA110 in both 
antigen of pure culture and nodule. 
Visualization of DOA9 bacteroids in nodule sample and bacterial cells in pure 
culture sample by using fluorescence microscopic technique validated the specificity 
and affinity of phage antibody RB8, RG9, and RD6/2 phage clones with target DOA9. 
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Figure 4.12 Immunofluorescence microscopy of polyclonal antibody and 
recombinant rabbit scFv phage antibodies with some bradyrhizobial 
antigens in form of pure culture and nodule bacteroid. RB8 and RG9 
clones from immunized rabbit library; 3C1 clone from naïve human 
library against aflatoxin (for negative control). For pure culture, scale bar 
is 10 µm and magnification is 80×; for nodule sample scale bar is 100 
µm and magnification is 10×. 
 
4.5 Sequence analysis of specific clones and 3D structure prediction 
The DNA sequence of positive clones, RD6/2, RB8 and RG9 were confirmed 
by automated DNA sequencing. The result indicated that the sequence of clone RB8 
and RG9 were identical. Then, the DNA sequences of phage clone RB8 and RD6/2 
were analyzed by using IMGT® software (http://www.imgt.org/IMGT_vquest/ 
vquest). The result showed that the RB8 phage clone belonged to rabbit 
immunoglobulin VH1 heavy chain and VL λ light chain families. The RD6/2 phage 
clone belonged to human immunoglobulin VH4 heavy chain and VLĸ light chain 
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families. Table 4.2 showed the origin of germline and family of the VH and VL genes 
and the amino acid changing with germline of the two recombinant scFv antibodies. 
 
Table 4.2 Germlines and Families of VH and VL segments of two positive clones. 
 
Clones 
 
Fragment 
 
Germline 
 
Amino â 
change 
number 
 
Family 
 
RB8 (Immunized rabbit library) 
 
VH 
VL 
 
IGHV1S69*01 
IGLV4S4*01 
 
7 
7 
 
VH1 
VLλ 
RD6/2 (Naïve human library) VH 
VL 
IGHV4­59*01 
IGKV3­20*01 
17 
0 
VH4 
VLĸ 
 
 
 
Figure 4.13 Deduced amino acid sequence of RB8 and RD6/2 clones, the sequence 
of complementary determining regions (CDR) of VH and VL chains and 
linker were underlined. 
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Figure 4.13 showed the amino acid sequence alignment of two recombinant 
scFv clones, RD6/2 and RB8, with the complementary determining regions (CDRs) of 
the VH and VL and the linker sequence domains were indicated. 
Antibodies or immunoglobulins are fascinating molecules from both a 
functional and structural point of view. They have the ability to recognize virtually 
any foreign molecule with exquisite specificity and very high affinity. These 
properties are brought about by their three dimensional (3D) structure architecture, 
which consists of a tetramer of two identical pairs of polypeptide chains: the heavy 
and light chains. Each chain includes homologous domains that have a similar tertiary 
structure to each other: the so­called immunoglobulin fold. The two N­terminal 
domains of the polypeptide chains are called variable domains (VL and VH, 
respectively), and they are responsible for antigen binding. Predicting the structure of 
an antibody from its amino acid sequence has several important applications. The 
structural models obtained once such predictions have been made can be used in 
docking simulations to identify the region of the antigen recognized by the antibody. 
Predicting the structure of antibodies also has implications for the re­design of 
biotechnologically useful antibodies adopted in a variety of experimental setups. 
For prediction of 3D structure, the nucleotide sequence of RB8 and RD6/2 
were translated to an amino acid sequence using Expasy (http://web.expasy.org/ 
translate/). The recombinant antibody structures were predicted using the Phyre 
program via the site at http://www.sbg.bio.ic.ac.uk/phyre2. The schematic three 
dimensional structure recombinant scFv antibody RB8 with CDRs was shown in 
Figure 4.14 and 4.15. 
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Figure 4.14 Three­dimensional structure modelling of recombinant rabbit scFv 
antibody RB8. 
 
 
 
 
Figure 4.15 Three­dimensional structure modelling of recombinant human scFv 
antibody RD6/2. 
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4.6 Production of soluble antibody fragments 
In order to express the scFv fragment in E. coli, the scFv genes of RD6/2 and 
RB8 phage clones were inserted into pET21b vector. Recombinant expression 
plasmid was transformed into E. coli HSM 174 for protein expression. This 
expression vector allows the expression of 6xHistidine­tag­fusion­proteins which 
using for purification and detection. The expression was performed overnight at 16°C 
with shaking. The secreted antibody could be found in the supernatant. The 
recombinant antibody scFv proteins were purified from the supernatant. After 
purification by immobilized metal ion affinity chromatography, the purify fraction 
were examined on SDS­PAGE gel (Figure 4.16). The results of SDS­PAGE showed 
that the scFv­hexahistidine fusion antibodies with a size of about 30kDa were 
successfully purified from the supernatant using Ni­NTA resin. 
 
 
Figure 4.16 SDS PAGE of purified scFv antibody from supernatant. A: RD6/2 phage 
clone; B: RB8 phage clone. Lane M, protein molecular weight marker; 
lane S, culture supernatant fraction; lane FT, flow­through fraction; lane 
W1, W2, W3, wash fraction; lane E1, E2, E3, E4: Elution. 
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The reactivity of recombinant antibodies after purification against DOA9 was 
tested by ELISA. The results were shown in Figure 4.17 and 4.18. The results 
demonstrated that the recombinant antibodies retained a specific binding activity for 
target DOA9 in both pure culture and nodules form of antigen as same as the phage 
scFv antibodies. 
 
 
Figure 4.17 ELISA of recombinant scFv antbodies against DOA9 and other antigens 
in pure culture sample. Value indicated mean of triplicate reactions. 
Error bars showed the standard deviation for each set of data. 
 
 
Figure 4.18 ELISA of recombinant scFv antbodies against DOA9 and other antigens 
in nodule samples. Value indicated mean of triplicate reactions. Error 
bars showed the standard deviation for each set. 
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4.7 Discussions 
Since DOA9 may have potential to be used as biofertilizer, DOA9 was used as 
a model in this study for development a new method for detection and monitoring of 
DOA9 in both pure culture and in form of bacteroid in legume nodules. Up to now, 
many techniques useful in the analysis of rhizobial inoculants have been developed by 
using antisera. However, it is very often to have cross­react with other rhizobial 
strains within the same species.  This cross­reactivity may also extend to other 
rhizobial biovars or species and sometimes even to members of other bacterial genera 
(Hoben et al. 1994). These cross­reactions are the main problem of using polyclonal 
antibody to detect and monitor specific rhizobium. In this study, the results clearly 
showed that polyclonal antibody produced from rabbit immunized with DOA9 have 
higher cross reactivity with other bacterial strains than that of phage antibodies. It 
may be due to these tested bacteria contain similar epitopes or antigens on their cells.  
Thus, polyclonal antibody which normally produced from various epitopes presented 
in DOA9, may have antibodies that probably bind to those similar antigens presence 
in other bacteria. 
Therefore, monoclonal antibodies are the ideal method and precise tools for 
bacterial identification that provides higher reliability for detection of rhizobial cell 
during production and application of biofertilizer. However, production of 
monoclonal antibodies by hybridoma technology is high cost and time consuming 
method. Phage display was first reported by George P. Smith (Smith 1985). It is an 
effective tool for producing a large diversity of peptides and proteins, and from these 
selecting molecules that have specific binding properties. This technique can be 
particularly useful for studying protein­ligand interactions, antigen­antibody 
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interactions and to improve the affinity of proteins for their binding properties (Smith 
and Petrenco.P.A. 1997). Production of recombinant antibodies by phage display 
technology has many advantages, such as small amounts of antigen, large scale and 
low cost. Single­chain antibody fragment (scFv) is a small engineered antibody, in 
which the variable heavy chain (VH) and light chain (VL) of the antibody molecule 
are connected by a short, flexible polypeptide linker. Using scFv for detection of 
antigen has several advantages. First, it retains the specific affinity to the antigen, 
though usually lower than its original antibody; second, scFv can be produced in large 
quantity in bacterial expression system at low cost; and third, it is easy to be 
manipulated to adapt different applications, for example, fusion with protein drug to 
target and kill pathogens or with marker molecules for detection purposes (Huang et 
al. 2012). Nowadays, scFv antibodies have considered as one of potential in 
immunological techniques for detecting and monitoring many targets such as: 
bacteria, virus, toxin, pesticides and other residues in both basic research and 
application research. 
In this study, I used two recombinant scFv antibody libraries for screening the 
best scFv antibodies for target, DOA9. The first library is naïve human library, the 
YAMO­I library. This library was constructed from 140 non­immunized (naïve) 
donors (Pansri et al. 2009). This library was applied in successful selections of 
specific antibodies against antigens, such as aflatoxin, crude snake venom, cancer cell 
surface, and rabies virus (Pansri et al. 2009, Rangnoi et al. 2011, Pruksametanan et al. 
2012). The second library was the immunized rabbit library that constructed by phage 
display technology. After bio­panning, one phage clone, RD6/2 (from human library) 
and two phage clones, RB8 and RG9 (from rabbit library) were selected to against 
target DOA9 with similar affinity. Interestingly, the scFv antibody specific to DOA9 
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was also successfully obtained from naïve human library in this study.  It could be 
possible that some of naïve donors may have experience exposed to some bacteria 
that have similar epitopes to DOA9. Moreover, it was noticed that only two scFv 
clones specific to DOA9 were obtained from rabbit library that immunized directly 
with this strain.  However, it is unclear to explain this phenomenon.  The recombinant 
scFv antibody were applied for detection of target DOA9 in both pure culture and 
nodule sample by phage ELISA and immunofluorescence assay comparing with 
polyclonal antibody against other bacterial strains.  Strain SUTN9­2 and SUTN1­12 
were in genus Bradyrhizobium isolated from Aeschynomene americana same as 
DOA9, while strain SUTN1­12 showed high similarity with strain DOA9 when 
compared by using gene multi locus analysis (Noisangiam et al., 2012).  However, the 
derived phage clones could be used to distinguish or have higher specificity to DOA9 
than SUTN1­12 or SUTN9­2.  Moreover, other bradyrhizobia and bacteria used as 
commercial biofertilizer, such as Bradyrhizobium diazoefficiens USDA110 for 
soybean, Bradyrhizobium sp. PRC008 for mungbean, Bradyrhizobium sp. TAL173 
for peanut, and other Plant Growth Promoting Rhizobacteria (PGPR) were included to 
test the cross­reactivity by using these antibodies.   Since these strains have been used 
as biofertilizer in the field for many years and some of them may persist in the soil, it 
is necessary to test whether the scFv antibodies derived from this study could bind or 
have the cross­reactivity with these commercial biofertilizer strains.  The results 
showed that, phage clones were more specific with target than polyclonal antibody 
and were also able to detect the bacteria in the root nodule. However, phage clones 
were not specific when applied directly for detecting the target bacterium in the soil. 
Thus, the result encourage more study to increasing the specific binding of the 
recombinant scFv antibody when applied directly with soil sample. 
89 
 
CHAPTER V 
CONCLUSION 
 
In conclusion, I successfully constructed the phage displayed rabbit scFv 
antibody library from the immunized rabbit with high quality. Then, the immunized 
rabbit scFv antibody library and the naïve human scFv antibody library were affinity 
selected against the target, Bradyrhizobium sp. strain DOA9 by biopanning. Two 
recombinant scFv antibodies were obtained from the immunized rabbit scFv antibody 
library. After sequencing, they were identical. From the naïve human scFv antibody 
library, one recombinant scFv antibody was obtained. The result was confirmed in 
two methods, phage enzyme linked immunosorbent assay and immunofluorescence 
assay with two sample types, pure culture and bacteroid in plant nodule. These 
antibodies have higher specificity than that of the polyclonal antibody and no cross­
reactivity with another tested bacterial strains. This study described the first time for 
the isolation of recombinant scFv antibody against N­fixing bacteria. The results 
encourage the further investigation of recombinant scFv antibody for the development 
new immunoassays for rapider and simpler detection of other bacteria using in 
agriculture as well as for studying in plant­microbe interaction. 
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